0000021076 false--06-30 Q3 2021 0000021076 2020-07-01 2021-03-31 xbrli:shares 0000021076 2021-04-16 iso4217:USD 0000021076 2021-01-01 2021-03-31 0000021076 2020-01-01 2020-03-31 0000021076 2019-07-01 2020-03-31 iso4217:USD xbrli:shares 0000021076 2021-03-31 0000021076 2020-06-30 0000021076 2019-06-30 0000021076 2020-03-31 xbrli:pure 0000021076 clx:JointVentureInKingdomOfSaudiArabiaMember 2020-07-09 0000021076 clx:JointVentureInKingdomOfSaudiArabiaMember 2020-07-09 0000021076 2020-07-09 2020-07-09 0000021076 clx:JointVentureInKingdomOfSaudiArabiaMember 2020-07-09 0000021076 2020-07-01 2020-12-31 0000021076 clx:JointVentureInKingdomOfSaudiArabiaMember 2020-07-09 2020-07-09 0000021076 clx:JointVentureInKingdomOfSaudiArabiaMember us-gaap:ContractualRightsMember 2020-07-09 0000021076 us-gaap:CustomerRelationshipsMember clx:JointVentureInKingdomOfSaudiArabiaMember 2020-07-09 0000021076 us-gaap:TrademarksMember 2021-01-01 2021-03-31 0000021076 us-gaap:OtherIntangibleAssetsMember 2021-01-01 2021-03-31 0000021076 clx:HealthAndWellnessMember 2020-06-30 0000021076 clx:HouseholdMember 2020-06-30 0000021076 clx:LifestyleMember 2020-06-30 0000021076 clx:InternationalMember 2020-06-30 0000021076 clx:HealthAndWellnessMember 2020-07-01 2020-09-30 0000021076 clx:HouseholdMember 2020-07-01 2020-09-30 0000021076 clx:LifestyleMember 2020-07-01 2020-09-30 0000021076 clx:InternationalMember 2020-07-01 2020-09-30 0000021076 2020-07-01 2020-09-30 0000021076 clx:HealthAndWellnessMember 2020-09-30 0000021076 clx:HouseholdMember 2020-09-30 0000021076 clx:LifestyleMember 2020-09-30 0000021076 clx:InternationalMember 2020-09-30 0000021076 2020-09-30 0000021076 clx:HealthAndWellnessMember 2020-10-01 2020-12-31 0000021076 clx:HouseholdMember 2020-10-01 2020-12-31 0000021076 clx:LifestyleMember 2020-10-01 2020-12-31 0000021076 clx:InternationalMember 2020-10-01 2020-12-31 0000021076 2020-10-01 2020-12-31 0000021076 clx:HealthAndWellnessMember 2020-12-31 0000021076 clx:HouseholdMember 2020-12-31 0000021076 clx:LifestyleMember 2020-12-31 0000021076 clx:InternationalMember 2020-12-31 0000021076 2020-12-31 0000021076 clx:HealthAndWellnessMember 2021-01-01 2021-03-31 0000021076 clx:HouseholdMember 2021-01-01 2021-03-31 0000021076 clx:LifestyleMember 2021-01-01 2021-03-31 0000021076 clx:InternationalMember 2021-01-01 2021-03-31 0000021076 clx:HealthAndWellnessMember 2021-03-31 0000021076 clx:HouseholdMember 2021-03-31 0000021076 clx:LifestyleMember 2021-03-31 0000021076 clx:InternationalMember 2021-03-31 0000021076 clx:JointVentureInKingdomOfSaudiArabiaMember 2020-10-01 2020-12-31 0000021076 clx:ImpairedTrademarksMember 2021-03-31 0000021076 us-gaap:TrademarksMember srt:WeightedAverageMember 2020-07-01 2021-03-31 0000021076 us-gaap:TrademarksMember 2021-03-31 0000021076 us-gaap:TrademarksMember 2020-07-01 2021-03-31 0000021076 us-gaap:TrademarksMember 2020-06-30 0000021076 us-gaap:TrademarksMember 2019-07-01 2020-06-30 0000021076 us-gaap:TrademarksMember 2021-03-31 0000021076 us-gaap:TrademarksMember 2020-06-30 0000021076 us-gaap:OtherIntangibleAssetsMember 2021-03-31 0000021076 us-gaap:OtherIntangibleAssetsMember 2020-06-30 0000021076 clx:TotalCommodityPurchaseDerivativeContractsMember 2020-07-01 2021-03-31 0000021076 clx:TotalCommodityPurchaseDerivativeContractsMember 2021-03-31 0000021076 clx:SoybeanOilFuturesMember 2021-03-31 0000021076 clx:JetFuelSwapsMember 2021-03-31 0000021076 clx:TotalCommodityPurchaseDerivativeContractsMember 2020-06-30 0000021076 clx:SoybeanOilFuturesMember 2020-06-30 0000021076 clx:JetFuelSwapsMember 2020-06-30 0000021076 clx:PurchasesofInventoryMember us-gaap:ForeignExchangeContractMember 2021-03-31 0000021076 clx:PurchasesofInventoryMember us-gaap:ForeignExchangeContractMember 2020-06-30 0000021076 us-gaap:InterestRateContractMember 2020-07-01 2021-03-31 0000021076 us-gaap:InterestRateContractMember 2021-03-31 0000021076 us-gaap:InterestRateContractMember 2020-06-30 0000021076 us-gaap:CommodityContractMember 2021-01-01 2021-03-31 0000021076 us-gaap:CommodityContractMember 2020-01-01 2020-03-31 0000021076 us-gaap:CommodityContractMember 2020-07-01 2021-03-31 0000021076 us-gaap:CommodityContractMember 2019-07-01 2020-03-31 0000021076 us-gaap:ForeignExchangeContractMember 2021-01-01 2021-03-31 0000021076 us-gaap:ForeignExchangeContractMember 2020-01-01 2020-03-31 0000021076 us-gaap:ForeignExchangeContractMember 2020-07-01 2021-03-31 0000021076 us-gaap:ForeignExchangeContractMember 2019-07-01 2020-03-31 0000021076 us-gaap:InterestRateContractMember 2021-01-01 2021-03-31 0000021076 us-gaap:InterestRateContractMember 2020-01-01 2020-03-31 0000021076 us-gaap:InterestRateContractMember 2019-07-01 2020-03-31 0000021076 clx:SoybeanOilFuturesMember us-gaap:CommodityContractMember 2021-03-31 0000021076 clx:SoybeanOilFuturesMember us-gaap:CommodityContractMember 2020-06-30 0000021076 us-gaap:FairValueInputsLevel1Member us-gaap:CommodityContractMember us-gaap:OtherCurrentAssetsMember us-gaap:CarryingReportedAmountFairValueDisclosureMember 2021-03-31 0000021076 us-gaap:FairValueInputsLevel1Member us-gaap:CommodityContractMember us-gaap:OtherCurrentAssetsMember us-gaap:EstimateOfFairValueFairValueDisclosureMember 2021-03-31 0000021076 us-gaap:FairValueInputsLevel1Member us-gaap:CommodityContractMember us-gaap:OtherCurrentAssetsMember us-gaap:CarryingReportedAmountFairValueDisclosureMember 2020-06-30 0000021076 us-gaap:FairValueInputsLevel1Member us-gaap:CommodityContractMember us-gaap:OtherCurrentAssetsMember us-gaap:EstimateOfFairValueFairValueDisclosureMember 2020-06-30 0000021076 us-gaap:FairValueInputsLevel2Member us-gaap:CommodityContractMember us-gaap:OtherCurrentAssetsMember us-gaap:CarryingReportedAmountFairValueDisclosureMember 2021-03-31 0000021076 us-gaap:FairValueInputsLevel2Member us-gaap:CommodityContractMember us-gaap:OtherCurrentAssetsMember us-gaap:EstimateOfFairValueFairValueDisclosureMember 2021-03-31 0000021076 us-gaap:FairValueInputsLevel2Member us-gaap:CommodityContractMember us-gaap:OtherCurrentAssetsMember us-gaap:CarryingReportedAmountFairValueDisclosureMember 2020-06-30 0000021076 us-gaap:FairValueInputsLevel2Member us-gaap:CommodityContractMember us-gaap:OtherCurrentAssetsMember us-gaap:EstimateOfFairValueFairValueDisclosureMember 2020-06-30 0000021076 us-gaap:FairValueInputsLevel2Member us-gaap:CommodityContractMember us-gaap:OtherAssetsMember us-gaap:CarryingReportedAmountFairValueDisclosureMember 2021-03-31 0000021076 us-gaap:FairValueInputsLevel2Member us-gaap:CommodityContractMember us-gaap:OtherAssetsMember us-gaap:EstimateOfFairValueFairValueDisclosureMember 2021-03-31 0000021076 us-gaap:FairValueInputsLevel2Member us-gaap:CommodityContractMember us-gaap:OtherAssetsMember us-gaap:CarryingReportedAmountFairValueDisclosureMember 2020-06-30 0000021076 us-gaap:FairValueInputsLevel2Member us-gaap:CommodityContractMember us-gaap:OtherAssetsMember us-gaap:EstimateOfFairValueFairValueDisclosureMember 2020-06-30 0000021076 us-gaap:FairValueInputsLevel2Member us-gaap:OtherAssetsMember us-gaap:InterestRateContractMember us-gaap:CarryingReportedAmountFairValueDisclosureMember 2021-03-31 0000021076 us-gaap:FairValueInputsLevel2Member us-gaap:OtherAssetsMember us-gaap:InterestRateContractMember us-gaap:EstimateOfFairValueFairValueDisclosureMember 2021-03-31 0000021076 us-gaap:FairValueInputsLevel2Member us-gaap:OtherAssetsMember us-gaap:InterestRateContractMember us-gaap:CarryingReportedAmountFairValueDisclosureMember 2020-06-30 0000021076 us-gaap:FairValueInputsLevel2Member us-gaap:OtherAssetsMember us-gaap:InterestRateContractMember us-gaap:EstimateOfFairValueFairValueDisclosureMember 2020-06-30 0000021076 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2021-03-31 0000021076 us-gaap:EstimateOfFairValueFairValueDisclosureMember 2021-03-31 0000021076 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2020-06-30 0000021076 us-gaap:EstimateOfFairValueFairValueDisclosureMember 2020-06-30 0000021076 us-gaap:FairValueInputsLevel1Member us-gaap:AccountsPayableAndAccruedLiabilitiesMember us-gaap:CommodityContractMember us-gaap:CarryingReportedAmountFairValueDisclosureMember 2021-03-31 0000021076 us-gaap:FairValueInputsLevel1Member us-gaap:AccountsPayableAndAccruedLiabilitiesMember us-gaap:CommodityContractMember us-gaap:EstimateOfFairValueFairValueDisclosureMember 2021-03-31 0000021076 us-gaap:FairValueInputsLevel1Member us-gaap:AccountsPayableAndAccruedLiabilitiesMember us-gaap:CommodityContractMember us-gaap:CarryingReportedAmountFairValueDisclosureMember 2020-06-30 0000021076 us-gaap:FairValueInputsLevel1Member us-gaap:AccountsPayableAndAccruedLiabilitiesMember us-gaap:CommodityContractMember us-gaap:EstimateOfFairValueFairValueDisclosureMember 2020-06-30 0000021076 us-gaap:FairValueInputsLevel2Member us-gaap:AccountsPayableAndAccruedLiabilitiesMember us-gaap:CommodityContractMember us-gaap:CarryingReportedAmountFairValueDisclosureMember 2021-03-31 0000021076 us-gaap:FairValueInputsLevel2Member us-gaap:AccountsPayableAndAccruedLiabilitiesMember us-gaap:CommodityContractMember us-gaap:EstimateOfFairValueFairValueDisclosureMember 2021-03-31 0000021076 us-gaap:FairValueInputsLevel2Member us-gaap:AccountsPayableAndAccruedLiabilitiesMember us-gaap:CommodityContractMember us-gaap:CarryingReportedAmountFairValueDisclosureMember 2020-06-30 0000021076 us-gaap:FairValueInputsLevel2Member us-gaap:AccountsPayableAndAccruedLiabilitiesMember us-gaap:CommodityContractMember us-gaap:EstimateOfFairValueFairValueDisclosureMember 2020-06-30 0000021076 us-gaap:FairValueInputsLevel2Member us-gaap:AccountsPayableAndAccruedLiabilitiesMember us-gaap:ForeignExchangeForwardMember us-gaap:CarryingReportedAmountFairValueDisclosureMember 2021-03-31 0000021076 us-gaap:FairValueInputsLevel2Member us-gaap:AccountsPayableAndAccruedLiabilitiesMember us-gaap:ForeignExchangeForwardMember us-gaap:EstimateOfFairValueFairValueDisclosureMember 2021-03-31 0000021076 us-gaap:FairValueInputsLevel2Member us-gaap:AccountsPayableAndAccruedLiabilitiesMember us-gaap:ForeignExchangeForwardMember us-gaap:CarryingReportedAmountFairValueDisclosureMember 2020-06-30 0000021076 us-gaap:FairValueInputsLevel2Member us-gaap:AccountsPayableAndAccruedLiabilitiesMember us-gaap:ForeignExchangeForwardMember us-gaap:EstimateOfFairValueFairValueDisclosureMember 2020-06-30 0000021076 us-gaap:FairValueInputsLevel1Member us-gaap:MoneyMarketFundsMember us-gaap:CashAndCashEquivalentsMember us-gaap:CarryingReportedAmountFairValueDisclosureMember 2021-03-31 0000021076 us-gaap:FairValueInputsLevel1Member us-gaap:MoneyMarketFundsMember us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:CashAndCashEquivalentsMember 2021-03-31 0000021076 us-gaap:FairValueInputsLevel1Member us-gaap:MoneyMarketFundsMember us-gaap:CashAndCashEquivalentsMember us-gaap:CarryingReportedAmountFairValueDisclosureMember 2020-06-30 0000021076 us-gaap:FairValueInputsLevel1Member us-gaap:MoneyMarketFundsMember us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:CashAndCashEquivalentsMember 2020-06-30 0000021076 us-gaap:FairValueInputsLevel2Member us-gaap:BankTimeDepositsMember us-gaap:CashAndCashEquivalentsMember us-gaap:CarryingReportedAmountFairValueDisclosureMember 2021-03-31 0000021076 us-gaap:FairValueInputsLevel2Member us-gaap:BankTimeDepositsMember us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:CashAndCashEquivalentsMember 2021-03-31 0000021076 us-gaap:FairValueInputsLevel2Member us-gaap:BankTimeDepositsMember us-gaap:CashAndCashEquivalentsMember us-gaap:CarryingReportedAmountFairValueDisclosureMember 2020-06-30 0000021076 us-gaap:FairValueInputsLevel2Member us-gaap:BankTimeDepositsMember us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:CashAndCashEquivalentsMember 2020-06-30 0000021076 us-gaap:FairValueInputsLevel1Member us-gaap:OtherAssetsMember us-gaap:CarryingReportedAmountFairValueDisclosureMember clx:TrustAssetsForNonqualifiedDeferredCompensationPlansMember 2021-03-31 0000021076 us-gaap:FairValueInputsLevel1Member us-gaap:OtherAssetsMember us-gaap:EstimateOfFairValueFairValueDisclosureMember clx:TrustAssetsForNonqualifiedDeferredCompensationPlansMember 2021-03-31 0000021076 us-gaap:FairValueInputsLevel1Member us-gaap:OtherAssetsMember us-gaap:CarryingReportedAmountFairValueDisclosureMember clx:TrustAssetsForNonqualifiedDeferredCompensationPlansMember 2020-06-30 0000021076 us-gaap:FairValueInputsLevel1Member us-gaap:OtherAssetsMember us-gaap:EstimateOfFairValueFairValueDisclosureMember clx:TrustAssetsForNonqualifiedDeferredCompensationPlansMember 2020-06-30 0000021076 us-gaap:FairValueInputsLevel2Member clx:CurrentMaturitiesOfLongTermDebtAndLongTermDebtMember us-gaap:LongTermDebtMember us-gaap:CarryingReportedAmountFairValueDisclosureMember 2021-03-31 0000021076 us-gaap:FairValueInputsLevel2Member clx:CurrentMaturitiesOfLongTermDebtAndLongTermDebtMember us-gaap:LongTermDebtMember us-gaap:EstimateOfFairValueFairValueDisclosureMember 2021-03-31 0000021076 us-gaap:FairValueInputsLevel2Member clx:CurrentMaturitiesOfLongTermDebtAndLongTermDebtMember us-gaap:LongTermDebtMember us-gaap:CarryingReportedAmountFairValueDisclosureMember 2020-06-30 0000021076 us-gaap:FairValueInputsLevel2Member clx:CurrentMaturitiesOfLongTermDebtAndLongTermDebtMember us-gaap:LongTermDebtMember us-gaap:EstimateOfFairValueFairValueDisclosureMember 2020-06-30 0000021076 us-gaap:OtherAssetsMember 2021-01-01 2021-03-31 0000021076 us-gaap:CommonStockMember 2019-12-31 0000021076 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0000021076 us-gaap:RetainedEarningsMember 2019-12-31 0000021076 us-gaap:TreasuryStockMember 2019-12-31 0000021076 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0000021076 us-gaap:NoncontrollingInterestMember 2019-12-31 0000021076 2019-12-31 0000021076 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0000021076 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-03-31 0000021076 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0000021076 us-gaap:TreasuryStockMember 2020-01-01 2020-03-31 0000021076 us-gaap:CommonStockMember 2020-03-31 0000021076 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0000021076 us-gaap:RetainedEarningsMember 2020-03-31 0000021076 us-gaap:TreasuryStockMember 2020-03-31 0000021076 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-03-31 0000021076 us-gaap:NoncontrollingInterestMember 2020-03-31 0000021076 us-gaap:CommonStockMember 2020-12-31 0000021076 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0000021076 us-gaap:RetainedEarningsMember 2020-12-31 0000021076 us-gaap:TreasuryStockMember 2020-12-31 0000021076 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0000021076 us-gaap:NoncontrollingInterestMember 2020-12-31 0000021076 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0000021076 us-gaap:NoncontrollingInterestMember 2021-01-01 2021-03-31 0000021076 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-03-31 0000021076 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0000021076 us-gaap:TreasuryStockMember 2021-01-01 2021-03-31 0000021076 us-gaap:NoncontrollingInterestMember 2020-07-01 2021-03-31 0000021076 us-gaap:CommonStockMember 2021-03-31 0000021076 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0000021076 us-gaap:RetainedEarningsMember 2021-03-31 0000021076 us-gaap:TreasuryStockMember 2021-03-31 0000021076 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-03-31 0000021076 us-gaap:NoncontrollingInterestMember 2021-03-31 0000021076 us-gaap:CommonStockMember 2019-06-30 0000021076 us-gaap:AdditionalPaidInCapitalMember 2019-06-30 0000021076 us-gaap:RetainedEarningsMember 2019-06-30 0000021076 us-gaap:TreasuryStockMember 2019-06-30 0000021076 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-06-30 0000021076 us-gaap:NoncontrollingInterestMember 2019-06-30 0000021076 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:RetainedEarningsMember 2019-06-30 0000021076 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember 2019-06-30 0000021076 us-gaap:RetainedEarningsMember 2019-07-01 2020-03-31 0000021076 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-07-01 2020-03-31 0000021076 us-gaap:AdditionalPaidInCapitalMember 2019-07-01 2020-03-31 0000021076 us-gaap:TreasuryStockMember 2019-07-01 2020-03-31 0000021076 us-gaap:CommonStockMember 2020-06-30 0000021076 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0000021076 us-gaap:RetainedEarningsMember 2020-06-30 0000021076 us-gaap:TreasuryStockMember 2020-06-30 0000021076 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-06-30 0000021076 us-gaap:NoncontrollingInterestMember 2020-06-30 0000021076 us-gaap:RetainedEarningsMember 2020-07-01 2021-03-31 0000021076 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-07-01 2021-03-31 0000021076 us-gaap:AdditionalPaidInCapitalMember 2020-07-01 2021-03-31 0000021076 us-gaap:TreasuryStockMember 2020-07-01 2021-03-31 0000021076 us-gaap:CommonStockMember 2020-07-01 2021-03-31 0000021076 us-gaap:TreasuryStockMember 2020-11-18 2020-11-18 clx:repurchaseProgram 0000021076 clx:A2BillionOpenMarketPurchaseProgramMember 2021-03-31 0000021076 clx:EvergreenProgramMember 2021-03-31 0000021076 clx:A2BillionOpenMarketPurchaseProgramMember 2021-01-01 2021-03-31 0000021076 clx:A2BillionOpenMarketPurchaseProgramMember 2020-01-01 2020-03-31 0000021076 clx:A2BillionOpenMarketPurchaseProgramMember 2020-07-01 2021-03-31 0000021076 clx:A2BillionOpenMarketPurchaseProgramMember 2019-07-01 2020-03-31 0000021076 clx:EvergreenProgramMember 2021-01-01 2021-03-31 0000021076 clx:EvergreenProgramMember 2020-01-01 2020-03-31 0000021076 clx:EvergreenProgramMember 2020-07-01 2021-03-31 0000021076 clx:EvergreenProgramMember 2019-07-01 2020-03-31 0000021076 us-gaap:AccumulatedTranslationAdjustmentMember 2019-12-31 0000021076 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2019-12-31 0000021076 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2019-12-31 0000021076 us-gaap:AccumulatedTranslationAdjustmentMember 2020-01-01 2020-03-31 0000021076 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2020-01-01 2020-03-31 0000021076 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2020-01-01 2020-03-31 0000021076 us-gaap:AccumulatedTranslationAdjustmentMember 2020-03-31 0000021076 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2020-03-31 0000021076 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2020-03-31 0000021076 us-gaap:AccumulatedTranslationAdjustmentMember 2020-12-31 0000021076 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2020-12-31 0000021076 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2020-12-31 0000021076 us-gaap:AccumulatedTranslationAdjustmentMember 2021-01-01 2021-03-31 0000021076 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2021-01-01 2021-03-31 0000021076 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2021-01-01 2021-03-31 0000021076 us-gaap:AccumulatedTranslationAdjustmentMember 2021-03-31 0000021076 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2021-03-31 0000021076 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2021-03-31 0000021076 us-gaap:AccumulatedTranslationAdjustmentMember 2019-06-30 0000021076 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2019-06-30 0000021076 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2019-06-30 0000021076 us-gaap:AccumulatedTranslationAdjustmentMember 2019-07-01 2020-03-31 0000021076 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2019-07-01 2020-03-31 0000021076 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2019-07-01 2020-03-31 0000021076 us-gaap:AccumulatedTranslationAdjustmentMember 2020-06-30 0000021076 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2020-06-30 0000021076 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2020-06-30 0000021076 us-gaap:AccumulatedTranslationAdjustmentMember 2020-07-01 2021-03-31 0000021076 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2020-07-01 2021-03-31 0000021076 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2020-07-01 2021-03-31 0000021076 clx:LongTermInterCompanyLoansMember 2020-07-01 2021-03-31 0000021076 clx:LongTermInterCompanyLoansMember 2021-01-01 2021-03-31 0000021076 clx:LongTermInterCompanyLoansMember 2020-01-01 2020-03-31 0000021076 clx:LongTermInterCompanyLoansMember 2019-07-01 2020-03-31 0000021076 clx:RetirementIncomeMember us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2021-01-01 2021-03-31 0000021076 clx:RetirementIncomeMember us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2020-01-01 2020-03-31 0000021076 clx:RetirementIncomeMember us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2020-07-01 2021-03-31 0000021076 clx:RetirementIncomeMember us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2019-07-01 2020-03-31 0000021076 clx:RetirementIncomeMember country:US 2021-01-01 2021-03-31 0000021076 clx:RetirementIncomeMember country:US 2020-01-01 2020-03-31 0000021076 clx:RetirementIncomeMember country:US 2019-07-01 2020-03-31 0000021076 clx:RetirementIncomeMember country:US 2020-07-01 2021-03-31 0000021076 clx:AlamedaCountyCaliforniaMatterMember 2021-03-31 0000021076 clx:AlamedaCountyCaliforniaMatterMember 2020-06-30 0000021076 clx:AlamedaCountyCaliforniaMatterMember 2020-07-01 2021-03-31 0000021076 clx:AlamedaCountyCaliforniaMatterMember 2017-06-30 0000021076 clx:DickinsonCountyMichiganMatterMember 2020-06-30 0000021076 clx:DickinsonCountyMichiganMatterMember 2021-03-31 0000021076 clx:DickinsonCountyMichiganMatterMember 2020-07-01 2021-03-31 clx:reportableSegment 0000021076 clx:HealthAndWellnessMember us-gaap:OperatingSegmentsMember 2021-01-01 2021-03-31 0000021076 clx:HealthAndWellnessMember us-gaap:OperatingSegmentsMember 2020-01-01 2020-03-31 0000021076 clx:HealthAndWellnessMember us-gaap:OperatingSegmentsMember 2020-07-01 2021-03-31 0000021076 clx:HealthAndWellnessMember us-gaap:OperatingSegmentsMember 2019-07-01 2020-03-31 0000021076 us-gaap:OperatingSegmentsMember clx:HouseholdMember 2021-01-01 2021-03-31 0000021076 us-gaap:OperatingSegmentsMember clx:HouseholdMember 2020-01-01 2020-03-31 0000021076 us-gaap:OperatingSegmentsMember clx:HouseholdMember 2020-07-01 2021-03-31 0000021076 us-gaap:OperatingSegmentsMember clx:HouseholdMember 2019-07-01 2020-03-31 0000021076 us-gaap:OperatingSegmentsMember clx:LifestyleMember 2021-01-01 2021-03-31 0000021076 us-gaap:OperatingSegmentsMember clx:LifestyleMember 2020-01-01 2020-03-31 0000021076 us-gaap:OperatingSegmentsMember clx:LifestyleMember 2020-07-01 2021-03-31 0000021076 us-gaap:OperatingSegmentsMember clx:LifestyleMember 2019-07-01 2020-03-31 0000021076 us-gaap:OperatingSegmentsMember clx:InternationalMember 2021-01-01 2021-03-31 0000021076 us-gaap:OperatingSegmentsMember clx:InternationalMember 2020-01-01 2020-03-31 0000021076 us-gaap:OperatingSegmentsMember clx:InternationalMember 2020-07-01 2021-03-31 0000021076 us-gaap:OperatingSegmentsMember clx:InternationalMember 2019-07-01 2020-03-31 0000021076 us-gaap:CorporateNonSegmentMember 2021-01-01 2021-03-31 0000021076 us-gaap:CorporateNonSegmentMember 2020-01-01 2020-03-31 0000021076 us-gaap:CorporateNonSegmentMember 2020-07-01 2021-03-31 0000021076 us-gaap:CorporateNonSegmentMember 2019-07-01 2020-03-31 0000021076 us-gaap:CustomerConcentrationRiskMember clx:WalmartStoresIncMember us-gaap:RevenueFromContractWithCustomerMember 2021-01-01 2021-03-31 0000021076 us-gaap:CustomerConcentrationRiskMember clx:WalmartStoresIncMember us-gaap:RevenueFromContractWithCustomerMember 2020-07-01 2021-03-31 0000021076 us-gaap:CustomerConcentrationRiskMember clx:WalmartStoresIncMember us-gaap:RevenueFromContractWithCustomerMember 2020-01-01 2020-03-31 0000021076 us-gaap:CustomerConcentrationRiskMember clx:WalmartStoresIncMember us-gaap:RevenueFromContractWithCustomerMember 2019-07-01 2020-03-31 0000021076 clx:HealthAndWellnessMember clx:CleaningMember us-gaap:ProductConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2021-01-01 2021-03-31 0000021076 clx:HealthAndWellnessMember clx:CleaningMember us-gaap:ProductConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2020-01-01 2020-03-31 0000021076 clx:HealthAndWellnessMember clx:CleaningMember us-gaap:ProductConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2020-07-01 2021-03-31 0000021076 clx:HealthAndWellnessMember clx:CleaningMember us-gaap:ProductConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2019-07-01 2020-03-31 0000021076 clx:HealthAndWellnessMember clx:ProfessionalProductsMember us-gaap:ProductConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2021-01-01 2021-03-31 0000021076 clx:HealthAndWellnessMember clx:ProfessionalProductsMember us-gaap:ProductConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2020-01-01 2020-03-31 0000021076 clx:HealthAndWellnessMember clx:ProfessionalProductsMember us-gaap:ProductConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2020-07-01 2021-03-31 0000021076 clx:HealthAndWellnessMember clx:ProfessionalProductsMember us-gaap:ProductConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2019-07-01 2020-03-31 0000021076 clx:HealthAndWellnessMember clx:VitaminsMineralsAndSupplementsMember us-gaap:ProductConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2021-01-01 2021-03-31 0000021076 clx:HealthAndWellnessMember clx:VitaminsMineralsAndSupplementsMember us-gaap:ProductConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2020-01-01 2020-03-31 0000021076 clx:HealthAndWellnessMember clx:VitaminsMineralsAndSupplementsMember us-gaap:ProductConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2020-07-01 2021-03-31 0000021076 clx:HealthAndWellnessMember clx:VitaminsMineralsAndSupplementsMember us-gaap:ProductConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2019-07-01 2020-03-31 0000021076 clx:HealthAndWellnessMember us-gaap:ProductConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2021-01-01 2021-03-31 0000021076 clx:HealthAndWellnessMember us-gaap:ProductConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2020-01-01 2020-03-31 0000021076 clx:HealthAndWellnessMember us-gaap:ProductConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2020-07-01 2021-03-31 0000021076 clx:HealthAndWellnessMember us-gaap:ProductConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2019-07-01 2020-03-31 0000021076 clx:HouseholdMember clx:BagsWrapsAndContainersMember us-gaap:ProductConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2021-01-01 2021-03-31 0000021076 clx:HouseholdMember clx:BagsWrapsAndContainersMember us-gaap:ProductConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2020-01-01 2020-03-31 0000021076 clx:HouseholdMember clx:BagsWrapsAndContainersMember us-gaap:ProductConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2020-07-01 2021-03-31 0000021076 clx:HouseholdMember clx:BagsWrapsAndContainersMember us-gaap:ProductConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2019-07-01 2020-03-31 0000021076 clx:CatLitterMember clx:HouseholdMember us-gaap:ProductConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2021-01-01 2021-03-31 0000021076 clx:CatLitterMember clx:HouseholdMember us-gaap:ProductConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2020-01-01 2020-03-31 0000021076 clx:CatLitterMember clx:HouseholdMember us-gaap:ProductConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2020-07-01 2021-03-31 0000021076 clx:CatLitterMember clx:HouseholdMember us-gaap:ProductConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2019-07-01 2020-03-31 0000021076 clx:HouseholdMember us-gaap:ProductConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember clx:GrillingMember 2021-01-01 2021-03-31 0000021076 clx:HouseholdMember us-gaap:ProductConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember clx:GrillingMember 2020-01-01 2020-03-31 0000021076 clx:HouseholdMember us-gaap:ProductConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember clx:GrillingMember 2020-07-01 2021-03-31 0000021076 clx:HouseholdMember us-gaap:ProductConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember clx:GrillingMember 2019-07-01 2020-03-31 0000021076 clx:HouseholdMember us-gaap:ProductConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2021-01-01 2021-03-31 0000021076 clx:HouseholdMember us-gaap:ProductConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2020-01-01 2020-03-31 0000021076 clx:HouseholdMember us-gaap:ProductConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2020-07-01 2021-03-31 0000021076 clx:HouseholdMember us-gaap:ProductConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2019-07-01 2020-03-31 0000021076 clx:LifestyleMember us-gaap:ProductConcentrationRiskMember clx:FoodProductsMember us-gaap:RevenueFromContractWithCustomerMember 2021-01-01 2021-03-31 0000021076 clx:LifestyleMember us-gaap:ProductConcentrationRiskMember clx:FoodProductsMember us-gaap:RevenueFromContractWithCustomerMember 2020-01-01 2020-03-31 0000021076 clx:LifestyleMember us-gaap:ProductConcentrationRiskMember clx:FoodProductsMember us-gaap:RevenueFromContractWithCustomerMember 2020-07-01 2021-03-31 0000021076 clx:LifestyleMember us-gaap:ProductConcentrationRiskMember clx:FoodProductsMember us-gaap:RevenueFromContractWithCustomerMember 2019-07-01 2020-03-31 0000021076 clx:NaturalPersonalCareMember clx:LifestyleMember us-gaap:ProductConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2021-01-01 2021-03-31 0000021076 clx:NaturalPersonalCareMember clx:LifestyleMember us-gaap:ProductConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2020-01-01 2020-03-31 0000021076 clx:NaturalPersonalCareMember clx:LifestyleMember us-gaap:ProductConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2020-07-01 2021-03-31 0000021076 clx:NaturalPersonalCareMember clx:LifestyleMember us-gaap:ProductConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2019-07-01 2020-03-31 0000021076 clx:LifestyleMember us-gaap:ProductConcentrationRiskMember clx:WaterFiltrationMember us-gaap:RevenueFromContractWithCustomerMember 2021-01-01 2021-03-31 0000021076 clx:LifestyleMember us-gaap:ProductConcentrationRiskMember clx:WaterFiltrationMember us-gaap:RevenueFromContractWithCustomerMember 2020-01-01 2020-03-31 0000021076 clx:LifestyleMember us-gaap:ProductConcentrationRiskMember clx:WaterFiltrationMember us-gaap:RevenueFromContractWithCustomerMember 2020-07-01 2021-03-31 0000021076 clx:LifestyleMember us-gaap:ProductConcentrationRiskMember clx:WaterFiltrationMember us-gaap:RevenueFromContractWithCustomerMember 2019-07-01 2020-03-31 0000021076 clx:LifestyleMember us-gaap:ProductConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2021-01-01 2021-03-31 0000021076 clx:LifestyleMember us-gaap:ProductConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2020-01-01 2020-03-31 0000021076 clx:LifestyleMember us-gaap:ProductConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2020-07-01 2021-03-31 0000021076 clx:LifestyleMember us-gaap:ProductConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2019-07-01 2020-03-31 0000021076 clx:InternationalMember us-gaap:ProductConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2021-01-01 2021-03-31 0000021076 clx:InternationalMember us-gaap:ProductConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2020-01-01 2020-03-31 0000021076 clx:InternationalMember us-gaap:ProductConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2020-07-01 2021-03-31 0000021076 clx:InternationalMember us-gaap:ProductConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2019-07-01 2020-03-31 0000021076 us-gaap:ProductConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2021-01-01 2021-03-31 0000021076 us-gaap:ProductConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2020-01-01 2020-03-31 0000021076 us-gaap:ProductConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2020-07-01 2021-03-31 0000021076 us-gaap:ProductConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2019-07-01 2020-03-31

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q

(Mark One) |  |
☑ | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2021.
OR

☐ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to
Commission File Number: 1-07151
_________________________
THE CLOROX COMPANY
(Exact name of registrant as specified in its charter)

Delaware | 31-0595760
(State or other jurisdiction of | (I.R.S. Employer Identification No.)
incorporation or organization) |

1221 Broadway, Oakland, California, 94612-1888
(Address of principal executive offices) (Zip code)
(510) 271-7000
(Registrant’s telephone number, including area code)

(Former name, former address and former fiscal year, if changed since last report)
___________________
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading Symbol(s) | Name of each exchange on which registered
Common Stock - $1.00 par value | CLX | New York Stock Exchange

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☑ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☑ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer | ☑ | Accelerated filer | ☐ | Non-accelerated filer | ☐ | Smaller Reporting Company | ☐ | Emerging Growth Company | ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☑
As of April 16, 2021, there were 124,372,035 shares outstanding of the registrant’s common stock ($1.00 par value).

1

PART I – FINANCIAL INFORMATION
Item 1. Financial Statements
The Clorox Company
Condensed Consolidated Statements of Earnings and Comprehensive Income (Unaudited)
(Dollars in millions, except per share data)

|  | Three Months Ended |  | Nine Months Ended
|  | 3/31/2021 |  | 3/31/2020 |  | 3/31/2021 |  | 3/31/2020
Net sales |  | $ | 1,781 |  |  | $ | 1,783 |  |  | $ | 5,539 |  |  | $ | 4,738 |
Cost of products sold |  |  | 1,007 |  |  |  | 951 |  |  |  | 3,008 |  |  |  | 2,604 |
Gross profit |  |  | 774 |  |  |  | 832 |  |  |  | 2,531 |  |  |  | 2,134 |
Selling and administrative expenses |  |  | 237 |  |  |  | 269 |  |  |  | 744 |  |  |  | 690 |
Advertising costs |  |  | 200 |  |  |  | 184 |  |  |  | 566 |  |  |  | 461 |
Research and development costs |  |  | 32 |  |  |  | 39 |  |  |  | 104 |  |  |  | 103 |
Goodwill, trademark and other asset impairments |  |  | 329 |  |  |  | — |  |  |  | 329 |  |  |  | — |
Interest expense |  |  | 25 |  |  |  | 24 |  |  |  | 74 |  |  |  | 74 |
Other (income) expense, net |  |  | 10 |  |  |  | 19 |  |  |  | (85) |  |  |  | 16 |
Earnings (losses) before income taxes |  |  | (59) |  |  |  | 297 |  |  |  | 799 |  |  |  | 790 |
Income taxes |  |  | — |  |  |  | 56 |  |  |  | 180 |  |  |  | 161 |
Net earnings (losses) |  |  | (59) |  |  |  | 241 |  |  |  | 619 |  |  |  | 629 |
Less: Net earnings attributable to noncontrolling interests |  |  | 2 |  |  | — |  |  |  | 6 |  |  |  | — |
Net earnings (losses) attributable to Clorox |  | $ | (61) |  |  | $ | 241 |  |  | $ | 613 |  |  | $ | 629 |
Net earnings (losses) per share attributable to Clorox |  |  |  |  |  |  |  |  |  |  |  |
Basic net earnings (losses) per share |  | $ | (0.49) |  |  | $ | 1.92 |  |  | $ | 4.86 |  |  | $ | 5.01 |
Diluted net earnings (losses) per share |  | $ | (0.49) |  |  | $ | 1.89 |  |  | $ | 4.78 |  |  | $ | 4.94 |
Weighted average shares outstanding (in thousands) |  |  |  |  |  |  |  |  |  |  |  |
Basic |  |  | 125,610 |  |  |  | 125,661 |  |  |  | 126,057 |  |  |  | 125,641 |
Diluted |  |  | 125,610 |  |  |  | 127,328 |  |  |  | 128,030 |  |  |  | 127,236 |
Comprehensive income (loss) |  | $ | (37) |  |  | $ | 186 |  |  | $ | 706 |  |  | $ | 575 |
Less: Total comprehensive income attributable to noncontrolling interests |  |  | 2 |  |  | — |  |  |  | 6 |  |  |  | — |
Total comprehensive income (loss) attributable to Clorox |  | $ | (39) |  |  | $ | 186 |  |  | $ | 700 |  |  | $ | 575 |

See Notes to Condensed Consolidated Financial Statements (Unaudited)
2

The Clorox Company
Condensed Consolidated Balance Sheets
(Dollars in millions, except per share data)

| 3/31/2021 |  | 6/30/2020
| (Unaudited) |  |  |
ASSETS |  |  |  |  |
Current assets |  |  |  |  |
Cash and cash equivalents | $ | 492 |  |  | $ | 871 |
Receivables, net |  | 643 |  |  |  | 648 |
Inventories, net |  | 688 |  |  |  | 454 |
Prepaid expenses and other current assets |  | 139 |  |  |  | 47 |
Total current assets |  | 1,962 |  |  |  | 2,020 |
Property, plant and equipment, net of accumulated depreciation and amortization of $2,351 and $2,224, respectively |  | 1,251 |  |  |  | 1,103 |
Operating lease right-of-use assets |  | 328 |  |  |  | 291 |
Goodwill |  | 1,574 |  |  |  | 1,577 |
Trademarks, net |  | 694 |  |  |  | 785 |
Other intangible assets, net |  | 246 |  |  |  | 109 |
Other assets |  | 386 |  |  |  | 328 |
Total assets | $ | 6,441 |  |  | $ | 6,213 |
LIABILITIES AND STOCKHOLDERS’ EQUITY |  |  |  |  |
Current liabilities |  |  |  |  |
Current maturities of long-term debt | $ | 300 |  |  | $ | — |
Current operating lease liabilities |  | 74 |  |  |  | 64 |
Accounts payable and accrued liabilities |  | 1,445 |  |  |  | 1,329 |
Income taxes payable |  | — |  |  |  | 25 |
Total current liabilities |  | 1,819 |  |  |  | 1,418 |
Long-term debt |  | 2,483 |  |  |  | 2,780 |
Long-term operating lease liabilities |  | 305 |  |  |  | 278 |
Other liabilities |  | 819 |  |  |  | 767 |
Deferred income taxes |  | 77 |  |  |  | 62 |
Total liabilities |  | 5,503 |  |  |  | 5,305 |
Commitments and contingencies |  |  |  |  |
Stockholders’ equity |  |  |  |  |
Preferred stock: $1.00 par value; 5,000,000 shares authorized; none issued or outstanding |  | — |  |  |  | — |
Common stock: $1.00 par value; 750,000,000 shares authorized; 130,741,461 and 158,741,461 shares issued as of March 31, 2021 and June 30, 2020, respectively; and 124,359,712 and 126,198,606 shares outstanding as of March 31, 2021 and June 30, 2020, respectively |  | 131 |  |  |  | 159 |
Additional paid-in capital |  | 1,190 |  |  |  | 1,137 |
Retained earnings |  | 1,086 |  |  |  | 3,567 |
Treasury stock, at cost: 6,381,749 and 32,542,855 shares as of March 31, 2021 and June 30, 2020, respectively |  | (1,111) |  |  |  | (3,315) |
Accumulated other comprehensive net (loss) income |  | (553) |  |  |  | (640) |
Total Clorox stockholders’ equity |  | 743 |  |  |  | 908 |
Noncontrolling interests |  | 195 |  |  |  | — |
Total stockholders’ equity |  | 938 |  |  |  | 908 |
Total liabilities and stockholders’ equity | $ | 6,441 |  |  | $ | 6,213 |

See Notes to Condensed Consolidated Financial Statements (Unaudited)
3

The Clorox Company
Condensed Consolidated Statements of Cash Flows (Unaudited)
(Dollars in millions)

| Nine Months Ended
| 3/31/2021 |  | 3/31/2020
Operating activities: |  |  |  |  |
Net earnings | $ | 619 |  |  | $ | 629 |
Adjustments to reconcile net earnings to net cash provided by operations: |  |  |  |  |
Depreciation and amortization |  | 157 |  |  |  | 133 |
Stock-based compensation |  | 52 |  |  |  | 37 |
Deferred income taxes |  | (21) |  |  |  | 5 |
Goodwill, trademark and other asset impairments |  | 329 |  |  |  | — |
Other |  | (53) |  |  |  | 26 |
Changes in: |  |  |  |  |
Receivables, net |  | 46 |  |  |  | (102) |
Inventories, net |  | (220) |  |  |  | 50 |
Prepaid expenses and other current assets |  | (29) |  |  |  | (6) |
Accounts payable and accrued liabilities |  | 94 |  |  |  | 53 |
Operating lease right-of-use assets and liabilities, net |  | (1) |  |  |  | 7 |
Income taxes payable / prepaid |  | (80) |  |  |  | (26) |
Net cash provided by operations |  | 893 |  |  |  | 806 |
Investing activities: |  |  |  |  |
Capital expenditures |  | (232) |  |  |  | (158) |
Businesses acquired, net of cash acquired |  | (85) |  |  |  | — |
Other |  | (24) |  |  |  | 13 |
Net cash used for investing activities |  | (341) |  |  |  | (145) |
Financing activities: |  |  |  |  |
Notes and loans payable, net |  | — |  |  |  | 234 |
Treasury stock purchased |  | (605) |  |  |  | (225) |
Cash dividends paid to Clorox stockholders |  | (420) |  |  |  | (399) |
Cash dividends paid to noncontrolling interests |  | (18) |  |  |  | — |
Issuance of common stock for employee stock plans and other |  | 99 |  |  |  | 129 |
Net cash used for financing activities |  | (944) |  |  |  | (261) |
Effect of exchange rate changes on cash, cash equivalents, and restricted cash |  | 10 |  |  |  | (8) |
Net increase (decrease) in cash, cash equivalents, and restricted cash |  | (382) |  |  |  | 392 |
Cash, cash equivalents, and restricted cash: |  |  |  |  |
Beginning of period |  | 879 |  |  |  | 113 |
End of period | $ | 497 |  |  | $ | 505 |

See Notes to Condensed Consolidated Financial Statements (Unaudited)
4

The Clorox Company
Notes to Condensed Consolidated Financial Statements (Unaudited)
(Dollars in millions, except per share data)
NOTE 1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Basis of Presentation
The unaudited interim condensed consolidated financial statements for the three and nine months ended March 31, 2021 and 2020, in the opinion of management, reflect all adjustments (consisting of normal recurring accruals) necessary for a fair presentation of the consolidated results of operations, financial position and cash flows of The Clorox Company and its controlled subsidiaries (the Company) for the periods presented. However, the financial results for interim periods are not necessarily indicative of the results that may be expected for a full fiscal year or for any other future period.
Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States (U.S. GAAP) have been omitted or condensed pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (SEC). The information in this report should be read in conjunction with the Company’s Annual Report on Form 10-K filed with the SEC for the fiscal year ended June 30, 2020, which includes a complete set of footnote disclosures, including the Company’s significant accounting policies.
Recently Issued Accounting Standards
Recently Issued Accounting Standards Not Yet Adopted
In December 2019, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2019-12, “Income Taxes (ASC 740): Simplifying the Accounting for Income Taxes,” which improves consistency in the application of accounting for income taxes by removing certain exceptions to the general principles in ASC 740 and by clarifying and amending existing guidance. The standard will be effective for the Company beginning in the first quarter of fiscal year 2022, with early adoption permitted. The amendments that are related to changes in ownership of foreign equity method investments or foreign subsidiaries are to be applied on a modified retrospective basis through a cumulative-effect adjustment to retained earnings as of the beginning of the fiscal year of adoption. The amendments that are related to franchise taxes that are partially based on income are to be applied on either a retrospective basis for all periods presented or a modified retrospective basis through a cumulative-effect adjustment to retained earnings as of the beginning of the fiscal year of adoption. All other amendments under this ASU are to be applied on a prospective basis. The Company is currently evaluating the impact that the adoption of this guidance will have on its consolidated financial statements.
Recently Adopted Accounting Standards
In January 2017, the FASB issued ASU No. 2017-04, “Intangibles-Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment,” which eliminates the requirement to calculate the implied fair value of goodwill to measure a goodwill impairment charge. The Company adopted this guidance as of July 1, 2020 on a prospective basis, and the adoption did not have a material impact on the Company’s consolidated financial statements at the time of adoption. The impairment identified in the third quarter of fiscal year 2021 was calculated in accordance with this guidance. The future impact of this new standard will depend on the specific facts and circumstances of future impairments that may occur.
5

NOTE 2. BUSINESS ACQUIRED
Saudi Joint Venture Acquisition
On July 9, 2020, the Company increased its investment in each of the two entities comprising its joint venture in the Kingdom of Saudi Arabia (Saudi joint venture). The joint venture offers customers in the Gulf region a range of cleaning and disinfecting products. The Company had previously accounted for its 30 percent investment of $27 as of June 30, 2020, under the equity method of accounting. Subsequent to the closing of this transaction, the Company’s total ownership interest in each of the entities increased to 51 percent. The Company has consolidated this joint venture into the Company’s consolidated financial statements from the date of acquisition and reflects operations within the International reportable segment. The equity and income attributable to the other joint venture owners is recorded and presented as noncontrolling interests.
The total purchase consideration of $111 consisted of $100 cash paid, which was sourced from operations, and $11 from the net effective settlement of preexisting arrangements between the Company and the joint venture. The assets and liabilities of the joint venture were recorded at their respective estimated fair value as of the acquisition date using generally accepted accounting principles for business combinations. The excess of the purchase price over the fair value of the net identifiable assets acquired has been allocated to goodwill in the International reportable segment in the amount of $208. The goodwill is primarily attributable to the synergies expected to arise after the acquisition and reflects the value of further growth anticipated in the Gulf region. None of the goodwill is deductible for tax purposes.
As a result of this transaction, the carrying value of the Company’s previously held equity investment was remeasured to fair value, and resulted in an $85 non-recurring, non-cash gain recorded in Other (income) expense, net in the condensed consolidated statement of earnings and adjusted in Other operating activities in the condensed consolidated statement of cash flows for the first quarter of fiscal year 2021. The fair values of the noncontrolling interests and previously held equity interest were determined using a discounted cash flow (DCF) method under the income approach. Under this approach, the Company estimates future cash flows and discounts these cash flows at a rate of return that reflects the entities’ relative risk.
The purchase price allocation was finalized during the second quarter of fiscal year 2021. The following table summarizes the final purchase price allocation for the fair value of the joint venture’s assets acquired and liabilities assumed and the related deferred income taxes as of the acquisition date. The fair value of the assets acquired and liabilities assumed reflects the final insignificant measurement period adjustments related to goodwill, deferred income taxes and income taxes payable. The definite-lived intangibles acquired primarily represent the Company reacquiring previously licensed trademarks and customer relationships. The weighted-average estimated useful life of intangible assets subject to amortization is 9 years.

| Joint Venture
Goodwill | $ | 208 |
Reacquired rights (included in Other intangible assets, net) | 138 |
Property, plant and equipment | 46 |
Customer relationships (included in Other intangible assets, net) | 10 |
Working capital, net (includes cash acquired of $26) | 34 |
Noncurrent liabilities, net | (5) |
Deferred income taxes | (19) |
Total fair value of net assets | 412 |
Less: Fair value of noncontrolling interests | (198) |
Less: Fair value of previously held equity interest | (103) |
Total purchase consideration | $ | 111 |

Included in the Company’s results for the three and nine months ended March 31, 2021 was $19 and $65, respectively, of net sales from the joint venture. Pro forma results reflecting this transaction were not presented because it is not significant to the Company’s consolidated financial results.
6

NOTE 3. INVENTORIES, NET
Inventories, net, consisted of the following as of:

| 3/31/2021 |  | 6/30/2020
Finished goods | $ | 522 |  |  | $ | 340 |
Raw materials and packaging | 188 |  |  | 140 |
Work in process | 10 |  |  | 7 |
LIFO allowances | (32) |  |  | (33) |
Total | $ | 688 |  |  | $ | 454 |

NOTE 4. GOODWILL, TRADEMARK AND OTHER ASSETS IMPAIRMENTS
During the third quarter of fiscal 2021, as a result of lower than expected actual and projected net sales growth and operating performance for the Vitamins, Minerals and Supplements (VMS) strategic business unit (SBU), a strategic review was initiated by management that resulted in updated financial and operational plans. These events were considered a triggering event requiring interim impairment assessments to be performed on the VMS reporting unit, indefinite-lived trademarks and other assets. Based on the outcome of these assessments, the following pre-tax impairment charges were recorded:

| Impairment Charge
Goodwill | $ | 228 |
Trademarks, net | 86 |
Other intangible assets, net | 14 |
Property, plant and equipment, net | 1 |
Total | $ | 329 |

In connection with recognizing these impairment charges, the Company recognized tax benefits related to the impairments of $62 due to the partial tax deductibility of these charges.
The impairment charges are a result of a higher level of competitive activity than originally assumed, accelerated declines in the channel where the business is over-developed, and higher than anticipated investments to grow the business, which have adversely affected the assumptions used to determine the fair value of the respective assets held by the VMS reporting unit for growth and the estimates of expenses necessary to achieve that growth. These impairment charges are based on the Company’s current estimates regarding the future financial performance of the VMS SBU and macroeconomic factors.
To determine the fair value of the VMS reporting unit, the Company used a DCF method under the income approach. Under this approach, the Company estimated the future cash flows of the VMS reporting unit and discounted these cash flows at a rate of return that reflects its relative risk. The other key estimates and factors used in the DCF method include, but are not limited to, net sales and expense growth rates, and a terminal growth rate.
Changes in the carrying amount of Goodwill as of March 31, 2021 from June 30, 2020, were as follows:

| Goodwill
| Health and Wellness |  | Household |  | Lifestyle |  | International |  | Total
Balance as of June 30, 2020 | $ | 857 |  |  | $ | 85 |  |  | $ | 244 |  |  | $ | 391 |  |  | $ | 1,577 |
Acquisitions | — |  |  | — |  |  | — |  |  | 212 |  |  | 212 |
Translation adjustments and other | — |  |  | — |  |  | — |  |  | 4 |  |  | 4 |
Balance as of September 30, 2020 | 857 |  |  | 85 |  |  | 244 |  |  | 607 |  |  | 1,793 |
Translation adjustments and other (1) | — |  |  | — |  |  | — |  |  | 10 |  |  | 10 |
Balance as of December 31, 2020 | 857 |  |  | 85 |  |  | 244 |  |  | 617 |  |  | 1,803 |
Goodwill impairment | (228) |  |  | — |  |  | — |  |  | — |  |  | (228) |
Translation adjustments and other | — |  |  | — |  |  | — |  |  | (1) |  |  | (1) |
Balance as of March 31, 2021 | $ | 629 |  |  | $ | 85 |  |  | $ | 244 |  |  | $ | 616 |  |  | $ | 1,574 |

(1) Includes $(4) purchase price allocation adjustment related to the Saudi joint venture acquisition. Refer to Note 2 of the Notes to Condensed Consolidated Financial Statements.
7

To determine the estimated fair values of the VMS related indefinite-lived trademarks, which were included within the Health and Wellness reportable segment, the Company used the income approach. This approach requires significant judgments in determining the royalty rates and the assets’ estimated cash flows as well as the appropriate discount rates applied to those cash flows to determine fair value. In addition, the useful lives of the impaired trademarks, with a remaining net carrying value of $13 as of March 31, 2021, were changed from indefinite to definite beginning on April 1, 2021, which reflects the remaining expected useful lives of the trademarks based on the most recent financial and operational plans. The weighted-average estimated useful life of these trademarks is 16 years.
The following table summarizes the carrying amount of trademarks and other intangible assets as of March 31, 2021 and as of June 30, 2020:

| As of March 31, 2021 |  | As of June 30, 2020
| Gross carrying amount |  | Accumulated amortization / Impairments |  | Net carrying amount |  | Gross carrying amount |  | Accumulated amortization / Impairments |  | Net carrying amount
Trademarks not subject to amortization | $ | 769 |  |  | $ | 86 |  |  | $ | 683 |  |  | $ | 766 |  |  | $ | — |  |  | $ | 766 |
Trademarks subject to amortization | 47 |  |  | 36 |  |  | 11 |  |  | 47 |  |  | 28 |  |  | 19 |
Other intangible assets | 583 |  |  | 337 |  |  | 246 |  |  | 424 |  |  | 315 |  |  | 109 |
Total | $ | 1,399 |  |  | $ | 459 |  |  | $ | 940 |  |  | $ | 1,237 |  |  | $ | 343 |  |  | $ | 894 |

Amortization expense relating to the Company’s intangible assets was $8 and $23 for the three and nine months ended March 31, 2021, respectively, and $3 and $10 for the three and nine months ended March 31, 2020, respectively. Estimated amortization expense for these intangible assets is $8, $32, $30, $29 and $28 for the remainder of fiscal year 2021 and fiscal years 2022, 2023, 2024 and 2025, respectively.
NOTE 5. FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS
Financial Risk Management and Derivative Instruments
The Company is exposed to certain commodity, foreign currency and interest rate risks related to its ongoing business operations and uses derivative instruments to mitigate its exposure to these risks.
Commodity Price Risk Management
The Company may use commodity exchange traded futures and over-the-counter swap contracts, which are generally no longer than 2 years, to fix the price of a portion of its forecasted raw material requirements. Commodity purchase contracts are measured at fair value using market quotations obtained from the Chicago Board of Trade commodity futures exchange and commodity derivative dealers.
As of March 31, 2021, the notional amount of commodity derivatives was $24, of which $15 related to soybean oil futures used for the Food products business and $9 related to jet fuel swaps used for the Grilling business. As of June 30, 2020, the notional amount of commodity derivatives was $27, of which $14 related to soybean oil futures and $13 related to jet fuel swaps.
Foreign Currency Risk Management
The Company may also enter into certain over-the-counter derivative contracts to manage a portion of the Company’s forecasted foreign currency exposure associated with the purchase of inventory. These foreign currency contracts generally have durations of no longer than 2 years. The foreign exchange contracts are measured at fair value using information quoted by foreign exchange dealers.
The notional amounts of outstanding foreign currency forward contracts used by the Company’s subsidiaries to hedge forecasted purchases of inventory were $68 and $70, respectively, as of March 31, 2021 and June 30, 2020.
8

NOTE 5. FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Continued)
Interest Rate Risk Management
The Company may enter into over-the-counter interest rate forward or swap contracts to fix a portion of the benchmark interest rate prior to the anticipated issuance of fixed rate debt or to manage the Company’s level of fixed and floating rate debt. These interest rate forward or swap contracts historically have had durations of less than 3 years. The interest rate contracts are measured at fair value using information quoted by U.S. government bond and interest rate derivative dealers.
The notional amounts of outstanding interest rate contracts used by the Company were $300 and $225, respectively, as of March 31, 2021 and June 30, 2020. These contracts represent forward starting interest rate swap contracts with a maturity date of September 2022 to manage the exposure to interest rate volatility associated with future interest payments on a forecasted debt issuance.
Commodity, Foreign Exchange and Interest Rate Derivatives
The Company designates its commodity forward and futures contracts for forecasted purchases of raw materials, foreign currency forward contracts for forecasted purchases of inventory and interest rate forward contracts for forecasted interest payments as cash flow hedges.
The effects of derivative instruments designated as hedging instruments on Other comprehensive (loss) income and Net earnings were as follows:

| Gains (losses) recognized in Other comprehensive (loss) income
| Three Months Ended |  | Nine Months Ended
| 3/31/2021 |  | 3/31/2020 |  | 3/31/2021 |  | 3/31/2020
Commodity purchase derivative contracts | $ | 5 |  |  | $ | (11) |  |  | $ | 12 |  |  | $ | (8) |
Foreign exchange derivative contracts | 2 |  |  | 2 |  |  | (1) |  |  | 2 |
Interest rate derivative contracts | 26 |  |  | — |  |  | 36 |  |  | — |
Total | $ | 33 |  |  | $ | (9) |  |  | $ | 47 |  |  | $ | (6) |

| Location of Gains (losses) reclassified from Accumulated other comprehensive net (loss) income into Net earnings | Gains (losses) reclassified from Accumulated other comprehensive net (loss) income and recognized in Net earnings
|  | Three Months Ended |  | Nine Months Ended
|  | 3/31/2021 |  | 3/31/2020 |  | 3/31/2021 |  | 3/31/2020
Commodity purchase derivative contracts | Cost of products sold | $ | — |  |  | $ | — |  |  | $ | (2) |  |  | $ | (1) |
Foreign exchange derivative contracts | Cost of products sold | — |  |  | — |  |  | — |  |  | — |
Interest rate derivative contracts | Interest expense | (2) |  |  | (2) |  |  | (5) |  |  | (5) |
Total |  | $ | (2) |  |  | $ | (2) |  |  | $ | (7) |  |  | $ | (6) |

The estimated amount of the existing net gain (loss) in Accumulated other comprehensive net (loss) income as of March 31, 2021, that is expected to be reclassified into Net earnings (losses) within the next twelve months is $2.
9

NOTE 5. FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Continued)
Counterparty Risk Management and Derivative Contract Requirements
The Company utilizes a variety of financial institutions as counterparties for over-the-counter derivative instruments. The Company enters into agreements governing the use of over-the-counter derivative instruments and sets internal limits on the aggregate over-the-counter derivative instrument positions held with each counterparty. Certain terms of these agreements require the Company or the counterparty to post collateral when the fair value of the derivative instruments exceeds contractually-defined counterparty liability position limits. Of the over-the-counter derivative instruments in liability positions held as of March 31, 2021 and June 30, 2020, $1 and $3, respectively, contained such terms. As of March 31, 2021 and June 30, 2020, neither the Company nor any counterparty was required to post any collateral, as no counterparty liability position limits were exceeded.
Certain terms of the agreements governing the Company’s over-the-counter derivative instruments require the credit ratings, as assigned by Standard & Poor’s and Moody’s to the Company and its counterparties, to remain at a level equal to or better than the minimum of an investment grade credit rating. If the Company’s credit ratings were to fall below investment grade, the counterparties to the derivative instruments could request full collateralization on derivative instruments in net liability positions. As of both March 31, 2021 and June 30, 2020, the Company and each of its counterparties had been assigned investment grade ratings by both Standard & Poor’s and Moody’s.
Certain of the Company’s exchange-traded futures contracts used for commodity price risk management include requirements for the Company to post collateral in the form of a cash margin account held by the Company’s broker for trades conducted on that exchange. As of March 31, 2021 and June 30, 2020, the Company maintained cash margin balances related to exchange-traded futures contracts of $0 and $2, respectively, which are classified as Prepaid expenses and other current assets on the condensed consolidated balance sheets.
Trust Assets
The Company has held interests in mutual funds and cash equivalents as part of the trust assets related to its nonqualified deferred compensation plans. The participants in the nonqualified deferred compensation plans, who are the Company’s current and former employees, may select among certain mutual funds in which to invest their compensation deferrals in accordance with the terms of the plans and within the confines of the trusts, which hold the marketable securities. The trusts represent variable interest entities for which the Company is considered the primary beneficiary, and, therefore, trust assets are consolidated and included in Other assets in the condensed consolidated balance sheets. The interests in mutual funds are measured at fair value using quoted market prices. The Company has designated these marketable securities as trading investments.
Fair Value Measurements
Financial assets and liabilities measured at fair value on a recurring basis in the condensed consolidated balance sheets are required to be classified and disclosed in one of the following three categories of the fair value hierarchy:
Level 1: Quoted market prices in active markets for identical assets or liabilities.
Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data.
Level 3: Unobservable inputs reflecting the reporting entity’s own assumptions.
As of March 31, 2021 and June 30, 2020, the Company’s financial assets and liabilities that were measured at fair value on a recurring basis included derivative financial instruments, which were classified as either Level 1 or Level 2, and trust assets to fund the Company’s nonqualified deferred compensation plans, which were classified as Level 1.
10

NOTE 5. FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Continued)
All of the Company’s derivative instruments qualify for hedge accounting. The following table provides information about the balance sheet classification and the fair values of the Company’s derivative instruments:

|  |  |  |  | 3/31/2021 |  | 6/30/2020
| Balance Sheet Classification |  | Fair Value Hierarchy Level |  | Carrying Amount |  | Estimated Fair Value |  | Carrying Amount |  | Estimated Fair Value
Assets |  |  |  |  |  |  |  |  |  |  |
Commodity purchase futures contracts | Other current assets |  | 1 |  | $ | 3 |  |  | $ | 3 |  |  | $ | — |  |  | $ | — |
Commodity purchase swaps contracts | Other current assets |  | 2 |  | 2 |  |  | 2 |  |  | — |  |  | — |
Commodity purchase swaps contracts | Other assets |  | 2 |  | — |  |  | — |  |  | — |  |  | — |
Interest rate forward contracts | Other assets |  | 2 |  | 37 |  |  | 37 |  |  | 1 |  |  | 1 |
|  |  |  |  | $ | 42 |  |  | $ | 42 |  |  | $ | 1 |  |  | $ | 1 |
Liabilities |  |  |  |  |  |  |  |  |  |  |
Commodity purchase futures contracts | Accounts payable and accrued liabilities |  | 1 |  | $ | — |  |  | $ | — |  |  | $ | 1 |  |  | $ | 1 |
Commodity purchase swaps contracts | Accounts payable and accrued liabilities |  | 2 |  | — |  |  | — |  |  | 3 |  |  | 3 |
Foreign exchange forward contract | Accounts payable and accrued liabilities |  | 2 |  | 1 |  |  | 1 |  |  | 1 |  |  | 1 |
|  |  |  |  | $ | 1 |  |  | $ | 1 |  |  | $ | 5 |  |  | $ | 5 |

The following table provides information about the balance sheet classification and the fair values of the Company’s other assets and liabilities for which disclosure of fair value is required:

|  |  |  |  | 3/31/2021 |  | 6/30/2020
| Balance Sheet Classification |  | Fair Value Hierarchy Level |  | Carrying Amount |  | Estimated Fair Value |  | Carrying Amount |  | Estimated Fair Value
Assets |  |  |  |  |  |  |  |  |  |  |
Investments, including money market funds | Cash and cash equivalents (1) |  | 1 |  | $ | 213 |  |  | $ | 213 |  |  | $ | 584 |  |  | $ | 584 |
Time deposits | Cash and cash equivalents (1) |  | 2 |  | 146 |  |  | 146 |  |  | 165 |  |  | 165 |
Trust assets for nonqualified deferred compensation plans | Other assets |  | 1 |  | 131 |  |  | 131 |  |  | 100 |  |  | 100 |
|  |  |  |  | $ | 490 |  |  | $ | 490 |  |  | $ | 849 |  |  | $ | 849 |
Liabilities |  |  |  |  |  |  |  |  |  |  |
Current maturities of long-term debt and Long-term debt | Current maturities of long- term debt and Long-term debt (2) |  | 2 |  | 2,783 |  |  | 2,944 |  |  | 2,780 |  |  | 3,051 |
|  |  |  |  | $ | 2,783 |  |  | $ | 2,944 |  |  | $ | 2,780 |  |  | $ | 3,051 |

____________________
(1)Cash and cash equivalents are composed of time deposits and other interest bearing investments, including money market funds with original maturity dates of 90 days or less. Cash and cash equivalents are recorded at cost, which approximates fair value.
(2)Current maturities of long-term debt and Long-term debt are recorded at cost. The fair value of Long-term debt, including current maturities, was determined using secondary market prices quoted by corporate bond dealers, and is classified as Level 2.
Furthermore, impairment charges of $329 were recorded during the third quarter of fiscal 2021, of which $228, $86, and $15 related to the goodwill of the VMS reporting unit, certain indefinite-lived trademarks and other assets, respectively. These adjustments were included as non-cash charges in the condensed consolidated statement of earnings. The non-recurring fair values utilized included unobservable Level 3 inputs based on management’s best estimates and assumptions. For additional information, refer to Note 4 of the Notes to Condensed Consolidated Financial Statements
11

NOTE 6. INCOME TAXES
In determining its quarterly provision for income taxes, the Company uses an estimated annual effective tax rate, which is based on expected annual income, statutory tax rates and tax planning opportunities available in the various jurisdictions in which the Company operates. Certain significant or unusual items are separately recognized in the quarter in which they occur and can be a source of variability in the effective tax rates from quarter to quarter. The effective tax rate on earnings (losses) was (1.4)% and 22.5% for the current three and nine months ended March 31, 2021, respectively, and 18.9% and 20.4% for the prior three and nine months ended March 31, 2020, respectively. The substantially lower tax rate on loss before income taxes in the current three month period and higher tax rate on earnings before income taxes in the current nine month period were driven by the partial non-deductibility of impaired VMS goodwill.
NOTE 7. NET EARNINGS (LOSSES) PER SHARE (EPS)
The following is the reconciliation of the weighted average number of shares outstanding (in thousands) used to calculate basic net EPS to those used to calculate diluted net EPS:

| Three Months Ended |  | Nine Months Ended
| 3/31/2021 |  | 3/31/2020 |  | 3/31/2021 |  | 3/31/2020
Basic | 125,610 |  | 125,661 |  | 126,057 |  | 125,641
Dilutive effect of stock options and other | — |  | 1,667 |  | 1,973 |  | 1,595
Diluted | 125,610 |  | 127,328 |  | 128,030 |  | 127,236
Antidilutive stock options and other | 4,826 |  | — |  |  | 428 |  |  | 2 |

Basic net earnings (losses) per share and Diluted net earnings (losses) per share are calculated on Net earnings (losses) attributable to Clorox.
Since the Company generated net losses attributable to Clorox for the three months ended March 31, 2021, there was no dilutive effect of stock options and other instruments because their impact would be antidilutive.
NOTE 8. COMPREHENSIVE INCOME (LOSS)
The following table provides a summary of Comprehensive income (loss) for the periods indicated:

| Three Months Ended |  | Nine Months Ended
| 3/31/2021 |  | 3/31/2020 |  | 3/31/2021 |  | 3/31/2020
Net earnings (losses) | $ | (59) |  |  | $ | 241 |  |  | $ | 619 |  |  | $ | 629 |
Other comprehensive (loss) income, net of tax: |  |  |  |  |  |  |
Foreign currency translation adjustments | (7) |  |  | (51) |  |  | 40 |  |  | (58) |
Net unrealized gains (losses) on derivatives | 27 |  |  | (5) |  |  | 42 |  |  | 1 |
Pension and postretirement benefit adjustments | 2 |  |  | 1 |  |  | 5 |  |  | 3 |
Total other comprehensive (loss) income, net of tax | 22 |  |  | (55) |  |  | 87 |  |  | (54) |
Comprehensive income (loss) | (37) |  |  | 186 |  |  | 706 |  |  | 575 |
Less: Total comprehensive income attributable to noncontrolling interests | 2 |  |  | — |  |  | 6 |  |  | — |
Total comprehensive income (loss) attributable to Clorox | $ | (39) |  |  | $ | 186 |  |  | $ | 700 |  |  | $ | 575 |

12

NOTE 9. STOCKHOLDERS’ EQUITY
Changes in the components of Stockholders’ equity were as follows for the periods indicated:

| Three Months Ended March 31
(Dollars in millions except per share data; shares in thousands) | Common Stock |  | Additional Paid-in Capital |  | Retained Earnings |  | Treasury Stock |  | Accumulated Other Comprehensive Net (Loss) Income |  | Non-controlling interests |  | Total Stockholders’ Equity
Amount |  | Shares |  |  |  | Amount |  | Shares |  |  |
Balance as of December 31, 2019 | $ | 159 |  |  | 158,741 |  |  | $ | 1,062 |  |  | $ | 3,292 |  |  | $ | (3,357) |  |  | (33,717) |  |  | $ | (601) |  |  | $ | — |  |  | $ | 555 |
Net earnings | — |  |  | — |  |  | — |  |  | 241 |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 241 |
Other comprehensive (loss) income | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | (55) |  |  | — |  |  | (55) |
Dividends to Clorox stockholders ($1.06 per share declared) | — |  |  | — |  |  | — |  |  | (135) |  |  | — |  |  | — |  |  | — |  |  | — |  |  | (135) |
Stock-based compensation | — |  |  | — |  |  | 18 |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 18 |
Other employee stock plan activities | — |  |  | — |  |  | 31 |  |  | — |  |  | 70 |  |  | 1,083 |  |  | — |  |  | — |  |  | 101 |
Treasury stock purchased | — |  |  | — |  |  | — |  |  | — |  |  | (30) |  |  | (184) |  |  | — |  |  | — |  |  | (30) |
Balance as of March 31, 2020 | $ | 159 |  |  | 158,741 |  |  | $ | 1,111 |  |  | $ | 3,398 |  |  | $ | (3,317) |  |  | (32,818) |  |  | $ | (656) |  |  | $ | — |  |  | $ | 695 |
Balance as of December 31, 2020 | $ | 131 |  |  | 130,741 |  |  | $ | 1,176 |  |  | $ | 1,302 |  |  | $ | (850) |  |  | (5,017) |  |  | $ | (575) |  |  | $ | 196 |  |  | $ | 1,380 |
Net earnings (losses) | — |  |  | — |  |  | — |  |  | (61) |  |  | — |  |  | — |  |  | — |  |  | 2 |  |  | (59) |
Other comprehensive (loss) income | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 22 |  |  | — |  |  | 22 |
Dividends to Clorox stockholders ($1.11 per share declared) | — |  |  | — |  |  | — |  |  | (139) |  |  | — |  |  | — |  |  | — |  |  | — |  |  | (139) |
Dividends to non-controlling interests | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | (3) |  |  | (3) |
Stock-based compensation | — |  |  | — |  |  | 17 |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 17 |
Other employee stock plan activities | — |  |  | — |  |  | (3) |  |  | (16) |  |  | 44 |  |  | 283 |  |  | — |  |  | — |  |  | 25 |
Treasury stock purchased | — |  |  | — |  |  | — |  |  | — |  |  | (305) |  |  | (1,648) |  |  | — |  |  | — |  |  | (305) |
Balance as of March 31, 2021 | $ | 131 |  |  | 130,741 |  |  | $ | 1,190 |  |  | $ | 1,086 |  |  | $ | (1,111) |  |  | (6,382) |  |  | $ | (553) |  |  | $ | 195 |  |  | $ | 938 |

13

NOTE 9. STOCKHOLDERS’ EQUITY (Continued)

| Nine Months Ended March 31
(Dollars in millions except per share data; shares in thousands) | Common Stock |  | Additional Paid-in Capital |  | Retained Earnings |  | Treasury Stock |  | Accumulated Other Comprehensive Net (Loss) Income |  | Non-controlling interests |  | Total Stockholders’ Equity
Amount |  | Shares |  |  |  | Amount |  | Shares |  |  |
Balance as of June 30, 2019 | $ | 159 |  |  | 158,741 |  |  | $ | 1,046 |  |  | $ | 3,150 |  |  | $ | (3,194) |  |  | (33,055) |  |  | $ | (602) |  |  | $ | — |  |  | $ | 559 |
Cumulative effect of accounting changes, net of tax (1) | — |  |  | — |  |  | — |  |  | 22 |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 22 |
Net earnings | — |  |  | — |  |  | — |  |  | 629 |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 629 |
Other comprehensive (loss) income | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | (54) |  |  | — |  |  | (54) |
Dividends to Clorox stockholders ($3.18 per share declared) | — |  |  | — |  |  | — |  |  | (402) |  |  | — |  |  | — |  |  | — |  |  | — |  |  | (402) |
Stock-based compensation | — |  |  | — |  |  | 37 |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 37 |
Other employee stock plan activities | — |  |  | — |  |  | 28 |  |  | (1) |  |  | 96 |  |  | 1,661 |  |  | — |  |  | — |  |  | 123 |
Treasury stock purchased | — |  |  | — |  |  | — |  |  | — |  |  | (219) |  |  | (1,424) |  |  | — |  |  | — |  |  | (219) |
Balance as of March 31, 2020 | $ | 159 |  |  | 158,741 |  |  | $ | 1,111 |  |  | $ | 3,398 |  |  | $ | (3,317) |  |  | (32,818) |  |  | $ | (656) |  |  | $ | — |  |  | $ | 695 |
Balance as of June 30, 2020 | $ | 159 |  |  | 158,741 |  |  | $ | 1,137 |  |  | $ | 3,567 |  |  | $ | (3,315) |  |  | (32,543) |  |  | $ | (640) |  |  | $ | — |  |  | $ | 908 |
Net earnings | — |  |  | — |  |  | — |  |  | 613 |  |  | — |  |  | — |  |  | — |  |  | 6 |  |  | 619 |
Other comprehensive (loss) income | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 87 |  |  | — |  |  | 87 |
Dividends to Clorox stockholders ($3.33 per share declared) | — |  |  | — |  |  | — |  |  | (421) |  |  | — |  |  | — |  |  | — |  |  | — |  |  | (421) |
Dividends to noncontrolling interests | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | (9) |  |  | (9) |
Business combinations including purchase accounting adjustments | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 198 |  |  | 198 |
Stock-based compensation | — |  |  | — |  |  | 52 |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 52 |
Other employee stock plan activities | — |  |  | — |  |  | 1 |  |  | (33) |  |  | 141 |  |  | 1,233 |  |  | — |  |  | — |  |  | 109 |
Treasury stock purchased | — |  |  | — |  |  | — |  |  | — |  |  | (605) |  |  | (3,072) |  |  | — |  |  | — |  |  | (605) |
Treasury stock retirement | (28) |  |  | (28,000) |  |  | — |  |  | (2,640) |  |  | 2,668 |  |  | 28,000 |  |  | — |  |  | — |  |  | — |
Balance as of March 31, 2021 | $ | 131 |  |  | 130,741 |  |  | $ | 1,190 |  |  | $ | 1,086 |  |  | $ | (1,111) |  |  | (6,382) |  |  | $ | (553) |  |  | $ | 195 |  |  | $ | 938 |

(1) As a result of adopting ASU No. 2016-02, “Leases (Topic 842),” on July 1, 2019, the Company recorded a cumulative effect of initially applying the new guidance as an adjustment to the fiscal year 2020 opening balance of Retained earnings.
On November 18, 2020 the Company retired 28 million shares of its treasury stock. These shares are now authorized but unissued. There was no effect on the Company’s overall equity position as a result of the retirement.
The Company has two stock repurchase programs: an open-market purchase program with an authorized aggregate purchase amount of up to $2,000, which has no expiration date, and a program to offset the anticipated impact of dilution related to stock-based awards (the Evergreen Program), which has no authorization limit on the dollar amount and no expiration date.
Stock repurchases under the two stock repurchase programs were as follows for the periods indicated:

| Three Months Ended |  | Nine Months Ended
| 3/31/2021 |  | 3/31/2020 |  | 3/31/2021 |  | 3/31/2020
| Amount |  | Shares (in thousands) |  | Amount |  | Shares (in thousands) |  | Amount |  | Shares (in thousands) |  | Amount |  | Shares (in thousands)
Open-market purchase program | $ | 200 |  |  | 1,088 |  |  | $ | — |  |  | — |  |  | $ | 200 |  |  | 1,088 |  |  | $ | 85 |  |  | 577 |
Evergreen Program | 105 |  |  | 560 |  |  | 30 |  |  | 184 |  |  | 405 |  |  | 1,984 |  |  | 134 |  |  | 847 |
Total stock repurchases | $ | 305 |  |  | 1,648 |  |  | $ | 30 |  |  | 184 |  |  | $ | 605 |  |  | 3,072 |  |  | $ | 219 |  |  | 1,424 |

14

NOTE 9. STOCKHOLDERS’ EQUITY (Continued)
Changes in Accumulated other comprehensive net (loss) income attributable to Clorox by component were as follows for the periods indicated:

| Three Months Ended March 31
| Foreign currency translation adjustments |  | Net unrealized gains (losses) on derivatives |  | Pension and postretirement benefit adjustments |  | Accumulated other comprehensive net (loss) income
Balance as of December 31, 2019 | $ | (421) |  |  | $ | (17) |  |  | $ | (163) |  |  | $ | (601) |
Other comprehensive (loss) income before reclassifications | (49) |  |  | (9) |  |  | — |  |  | (58) |
Amounts reclassified from Accumulated other comprehensive net (loss) income | — |  |  | 2 |  |  | 2 |  |  | 4 |
Income tax benefit (expense) | (2) |  |  | 2 |  |  | (1) |  |  | (1) |
Net current period other comprehensive (loss) income | (51) |  |  | (5) |  |  | 1 |  |  | (55) |
Balance as of March 31, 2020 | $ | (472) |  |  | $ | (22) |  |  | $ | (162) |  |  | $ | (656) |
Balance as of December 31, 2020 | $ | (403) |  |  | $ | (3) |  |  | $ | (169) |  |  | $ | (575) |
Other comprehensive (loss) income before reclassifications | (6) |  |  | 33 |  |  | — |  |  | 27 |
Amounts reclassified from Accumulated other comprehensive net (loss) income | — |  |  | 2 |  |  | 3 |  |  | 5 |
Income tax benefit (expense), and other | (1) |  |  | (8) |  |  | (1) |  |  | (10) |
Net current period other comprehensive (loss) income | (7) |  |  | 27 |  |  | 2 |  |  | 22 |
Balance as of March 31, 2021 | $ | (410) |  |  | $ | 24 |  |  | $ | (167) |  |  | $ | (553) |
| Nine Months Ended March 31
| Foreign currency translation adjustments |  | Net unrealized gains (losses) on derivatives |  | Pension and postretirement benefit adjustments |  | Accumulated other comprehensive net (loss) income
Balance as of June 30, 2019 | $ | (414) |  |  | $ | (23) |  |  | $ | (165) |  |  | $ | (602) |
Other comprehensive (loss) income before reclassifications | (55) |  |  | (6) |  |  | — |  |  | (61) |
Amounts reclassified from Accumulated other comprehensive net (loss) income | — |  |  | 6 |  |  | 5 |  |  | 11 |
Income tax benefit (expense) | (3) |  |  | 1 |  |  | (2) |  |  | (4) |
Net current period other comprehensive (loss) income | (58) |  |  | 1 |  |  | 3 |  |  | (54) |
Balance as of March 31, 2020 | $ | (472) |  |  | $ | (22) |  |  | $ | (162) |  |  | $ | (656) |
Balance as of June 30, 2020 | $ | (450) |  |  | $ | (18) |  |  | $ | (172) |  |  | $ | (640) |
Other comprehensive (loss) income before reclassifications | 38 |  |  | 47 |  |  | — |  |  | 85 |
Amounts reclassified from Accumulated other comprehensive net (loss) income | — |  |  | 7 |  |  | 7 |  |  | 14 |
Income tax benefit (expense), and other | 2 |  |  | (12) |  |  | (2) |  |  | (12) |
Net current period other comprehensive (loss) income | 40 |  |  | 42 |  |  | 5 |  |  | 87 |
Balance as of March 31, 2021 | $ | (410) |  |  | $ | 24 |  |  | $ | (167) |  |  | $ | (553) |

Included in foreign currency translation adjustments are re-measurement losses on long-term intercompany loans where settlement is not planned or anticipated in the foreseeable future. There were no amounts associated with these loans reclassified from Accumulated other comprehensive net (loss) income for the periods presented.
15

NOTE 10. EMPLOYEE BENEFIT PLANS
The following table summarizes the components of net periodic benefit cost for the Company’s retirement income plans:

| Three Months Ended |  | Nine Months Ended
| 3/31/2021 |  | 3/31/2020 |  | 3/31/2021 |  | 3/31/2020
Service cost | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | — |
Interest cost | 4 |  |  | 5 |  |  | 11 |  |  | 15 |
Expected return on plan assets (1) | (4) |  |  | (5) |  |  | (11) |  |  | (14) |
Amortization of unrecognized items | 3 |  |  | 3 |  |  | 8 |  |  | 7 |
Total | $ | 3 |  |  | $ | 3 |  |  | $ | 8 |  |  | $ | 8 |

(1) The weighted average long-term expected rate of return on plan assets used in computing the fiscal year 2021 net periodic benefit cost is 3.1%.
The net periodic benefit cost for the Company’s retirement health care plans was $0 for both the three months ended March 31, 2021 and 2020, and $(1) for both the nine months ended March 31, 2021 and 2020.
During the three months ended March 31, 2021 and 2020, the Company made $6 and $7 in contributions to its domestic retirement income plans, respectively. During the nine months ended March 31, 2021 and 2020, the Company made $10 in contributions to its domestic retirement income plans.
Net periodic benefit costs are reflected in Other (income) expense, net.
16

NOTE 11. OTHER CONTINGENCIES AND GUARANTEES
Contingencies
The Company is involved in certain environmental matters, including response actions at various locations. The Company had recorded liabilities totaling $27 and $28 as of March 31, 2021 and June 30, 2020, respectively, for its share of aggregate future remediation costs related to these matters.
One matter, which accounted for $14 of the recorded liability as of March 31, 2021 and June 30, 2020, relates to environmental costs associated with one of the Company’s former operations at a site located in Alameda County, California. In November 2016, at the request of regulators and with the assistance of environmental consultants, the Company submitted a Feasibility Study that evaluated various options for managing the site and included estimates of the related costs. As a result, the Company recorded in Other (income) expense, net an undiscounted liability for costs estimated to be incurred over a 30-year period, based on the option recommended in the Feasibility Study. However, as a result of ongoing discussions with regulators, in June 2017, the Company increased its recorded liability to $14, which reflects anticipated costs to implement additional remediation measures at this site. While the Company believes its latest estimate is reasonable, regulators could require the Company to implement one of the other options evaluated in the Feasibility Study, with estimated undiscounted costs of up to $28 over an estimated 30-year period, or require the Company to take other actions and incur costs not included in the study.
Another matter in Dickinson County, Michigan, at the site of one of the Company’s former operations for which the Company is jointly and severally liable, accounted for $10 of the recorded liability, as of March 31, 2021 and June 30, 2020. This amount reflects the Company’s agreement to be liable for 24.3% of the aggregate remediation and associated costs for this matter pursuant to a cost-sharing arrangement with a third party. If the third party is unable to pay its share of the response and remediation obligations, the Company may be responsible for such obligations. With the assistance of environmental consultants, the Company maintains an undiscounted liability representing its current best estimate of its share of the capital expenditures, maintenance and other costs that may be incurred over an estimated 30-year remediation period. Although it is reasonably possible that the Company’s exposure may exceed the amount recorded for the Dickinson County matter, any amount of such additional exposures, or range of exposures, is not estimable at this time. The Company’s estimated losses related to these matters are sensitive to a variety of uncertain factors, including the efficacy of any remediation efforts, changes in any remediation requirements, and the future availability of alternative clean-up technologies.
The Company is subject to various legal proceedings, claims and other loss contingencies, including, without limitation, loss contingencies relating to contractual arrangements, product liability, patents and trademarks, advertising, labor and employment, environmental, health and safety and other matters. With respect to these proceedings, claims and other loss contingencies, while considerable uncertainty exists, in the opinion of management at this time, the ultimate disposition of these matters, to the extent not previously provided for, will not have a material adverse effect, either individually or in the aggregate, on the Company’s condensed consolidated financial statements taken as a whole.
Guarantees
In conjunction with divestitures and other transactions, the Company may provide typical indemnifications (e.g., indemnifications for representations and warranties and retention of previously existing environmental, tax and employee liabilities) that have terms that vary in duration and in the potential amount of the total obligation and, in many circumstances, are not explicitly defined. The Company has not made, nor does it believe that it is probable that it will make, any material payments relating to its indemnifications, and believes that any reasonably possible payments would not have a material adverse effect, either individually or in the aggregate, on the Company’s condensed consolidated financial statements taken as a whole.
The Company had not recorded any material liabilities on the aforementioned guarantees as of March 31, 2021 and June 30, 2020.
As of March 31, 2021, the Company was party to a letter of credit of $11, related to one of its insurance carriers, of which $0 had been drawn upon.
17

NOTE 12. SEGMENT RESULTS
The Company operates through SBUs that are aggregated into four reportable segments based on the economics and nature of the products sold: Health and Wellness, Household, Lifestyle and International. Prior periods presented have been recast to reflect the reportable segment changes effective in the fourth quarter of fiscal year 2020.
Certain non-allocated administrative costs, interest income, interest expense and various other non-operating income and expenses are reflected in Corporate. Corporate assets include cash and cash equivalents, prepaid expenses and other current assets, property and equipment, operating lease right-of-use assets, other long-term assets and deferred taxes.
The tables below present reportable segment information and a reconciliation of the segment information to the Company’s consolidated Net sales and Earnings before income taxes, with amounts that are not allocated to the reportable segments reflected in Corporate.

|  | Net sales
|  | Three Months Ended |  | Nine Months Ended
|  | 3/31/2021 |  | 3/31/2020 |  | 3/31/2021 |  | 3/31/2020
Health and Wellness |  | $ | 680 |  |  | $ | 736 |  |  | $ | 2,310 |  |  | $ | 1,944 |
Household |  | 510 |  |  | 480 |  |  | 1,421 |  |  | 1,183 |
Lifestyle |  | 293 |  |  | 294 |  |  | 928 |  |  | 856 |
International |  | 298 |  |  | 273 |  |  | 880 |  |  | 755 |
Corporate |  | — |  |  | — |  |  | — |  |  | — |
Total |  | $ | 1,781 |  |  | $ | 1,783 |  |  | $ | 5,539 |  |  | $ | 4,738 |
|  | Earnings (losses) before income taxes
|  | Three Months Ended |  | Nine Months Ended
|  | 3/31/2021 |  | 3/31/2020 |  | 3/31/2021 |  | 3/31/2020
Health and Wellness (1) |  | $ | (183) |  |  | $ | 210 |  |  | $ | 315 |  |  | $ | 514 |
Household |  | 97 |  |  | 114 |  |  | 266 |  |  | 190 |
Lifestyle |  | 68 |  |  | 80 |  |  | 259 |  |  | 242 |
International |  | 30 |  |  | 36 |  |  | 184 |  |  | 106 |
Corporate |  | (71) |  |  | (143) |  |  | (225) |  |  | (262) |
Total |  | $ | (59) |  |  | $ | 297 |  |  | $ | 799 |  |  | $ | 790 |

(1) The earnings (losses) before income taxes for the Health and Wellness segment include a $329 non-cash goodwill, trademark and other asset impairment charge for the VMS SBU for the three and nine months ended March 31, 2021.
All intersegment sales are eliminated and are not included in the Company’s reportable segments’ net sales.
Net sales to the Company’s largest customer, Wal-Mart Stores, Inc. and its affiliates, as a percentage of consolidated net sales, were 24% for each of the three and nine months ended March 31, 2021, respectively, and 25% for each of the three and nine months ended March 31, 2020, respectively.
18

NOTE 12. SEGMENT RESULTS (Continued)
The following table provides Net sales as a percentage of the Company’s consolidated net sales for the Company’s SBUs and for the periods indicated:

|  | Net sales
|  | Three Months Ended |  | Nine Months Ended
|  | 3/31/2021 |  | 3/31/2020 |  | 3/31/2021 |  | 3/31/2020
Cleaning |  | 29 | % |  | 32 | % |  | 30 | % |  | 31 | %
Professional Products |  | 5 | % |  | 6 | % |  | 7 | % |  | 6 | %
Vitamins, Minerals and Supplements |  | 4 | % |  | 4 | % |  | 4 | % |  | 4 | %
Health and Wellness |  | 38 | % |  | 42 | % |  | 41 | % |  | 41 | %
Bags and Wraps |  | 11 | % |  | 11 | % |  | 11 | % |  | 12 | %
Cat Litter |  | 7 | % |  | 7 | % |  | 7 | % |  | 7 | %
Grilling |  | 11 | % |  | 9 | % |  | 8 | % |  | 6 | %
Household |  | 29 | % |  | 27 | % |  | 26 | % |  | 25 | %
Food Products |  | 10 | % |  | 8 | % |  | 9 | % |  | 9 | %
Natural Personal Care |  | 3 | % |  | 4 | % |  | 4 | % |  | 5 | %
Water Filtration |  | 3 | % |  | 4 | % |  | 4 | % |  | 4 | %
Lifestyle |  | 16 | % |  | 16 | % |  | 17 | % |  | 18 | %
International |  | 17 | % |  | 15 | % |  | 16 | % |  | 16 | %
Total |  | 100 | % |  | 100 | % |  | 100 | % |  | 100 | %

19

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
The Clorox Company
(Dollars in millions, except per share data)
Management’s Discussion and Analysis of Financial Condition and Results of Operations (MD&A) is designed to provide a reader of The Clorox Company’s (the Company or Clorox) financial statements with a narrative from the perspective of management on the Company’s financial condition, results of operations, liquidity and certain other factors that may affect future results. The following discussion of the Company’s financial condition and results of operations should be read in conjunction with MD&A and the consolidated financial statements and related notes included in the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2020, which was filed with the SEC on August 13, 2020, and the unaudited condensed consolidated financial statements and related notes contained in this Quarterly Report on Form 10-Q (this Report). Unless otherwise noted, MD&A compares the three and nine month periods ended March 31, 2021 (the current period) to the three and nine month periods ended March 31, 2020 (the prior period), with percentage and basis point calculations based on rounded numbers, except for per share data and the effective tax rate.
EXECUTIVE OVERVIEW
Clorox is a leading multinational manufacturer and marketer of consumer and professional products with approximately 8,800 employees worldwide. Clorox sells its products primarily through mass retailers, grocery outlets, warehouse clubs, dollar stores, home hardware centers, drug, pet and military stores, third-party and owned e-commerce channels, and distributors. Clorox markets some of the most trusted and recognized consumer brand names, including its namesake bleach and cleaning products, Pine-Sol® cleaners; Liquid-Plumr® clog removers; Poett® home care products; Fresh Step® cat litter; Glad® bags and wraps; Kingsford® grilling products; Hidden Valley® dressings; Brita® water-filtration products; Burt’s Bees® natural personal care products; and RenewLife®, Rainbow Light®, Natural Vitality®, NeoCell® and Stop Aging Now® vitamins, minerals and supplements. The Company also markets industry-leading products and technologies for professional customers, including those sold under the CloroxPro™ and the Clorox Healthcare® brand names. The Company has operations in more than 25 countries or territories and sells its products in more than 100 markets.
The Company primarily markets its leading brands in midsized categories considered to be financially attractive. Most of the Company’s products compete with other nationally advertised brands within each category and with “private label” brands.
The Company operates through strategic business units (SBUs) which are also the Company’s operating segments. These SBUs are then aggregated into four reportable segments. Prior periods presented have been recast to reflect the reportable segment changes effective in the fourth quarter of fiscal year 2020. The four reportable segments consist of the following:
•Health and Wellness consists of cleaning products, professional products, and vitamins, minerals and supplement products mainly marketed and sold in the U.S. Products within this segment include cleaning products such as laundry additives, including bleach products under the Clorox® brand and Clorox 2® stain fighter and color booster; home care products, primarily under the Clorox®, Clorox® Scentiva®, Formula 409®, Liquid-Plumr®, Pine-Sol® and Tilex® brands; professional cleaning and disinfecting products under the CloroxPro™, Clorox Healthcare®, and Clorox® Total 360® brands and professional food service products under the Hidden Valley® brand; and vitamins, minerals and supplement products under the RenewLife®, Rainbow Light®, Natural Vitality®, NeoCell® and Stop Aging Now® brands.
•Household consists of grilling products; bags and wraps; and cat litter products marketed and sold in the U.S. Products within this segment include grilling products under the Kingsford® and Kingsford® Match Light® brands; bags and wraps under the Glad® brand; and cat litter products under the Fresh Step®, Scoop Away® and Ever Clean® brands.
•Lifestyle consists of food products, water-filtration systems and filters, and natural personal care products marketed and sold in the U.S. Products within this segment include dressings and sauces, primarily under the Hidden Valley® brand; water-filtration systems and filters under the Brita® brand; and natural personal care products under the Burt’s Bees® brand.
20

•International consists of products sold outside the U.S. Products within this segment include laundry additives; home care products; water-filtration systems and filters; digestive health products; grilling products; cat litter products; food products; bags and wraps; natural personal care products; and professional cleaning and disinfecting products primarily under the Clorox®, Ayudin®, Clorinda®, Poett®, Pine-Sol®, Glad®, Brita®, RenewLife®, Ever Clean® and Burt’s Bees® brands.
RECENT EVENTS RELATED TO COVID-19
The novel coronavirus (COVID-19) pandemic has caused a severe global health crisis, along with economic and societal disruptions and uncertainties. As a result, we have taken an active role in addressing the ongoing pandemic’s impact on our employees, operations, customers, consumers, and communities, including taking precautionary measures, such as implementing contingency plans, making operational adjustments where necessary, and providing support to organizations that support front-line workers. The impact of COVID-19 and responses of governments, consumers, and others to the pandemic are affecting our business in many ways; however, we believe that the actions we are taking will help us emerge from this global pandemic operationally sound, and well positioned for continued long-term growth.
For our fiscal third quarter ended March 31, 2021, we continued to experience elevated demand for many of our products, especially our disinfecting cleaning products, in response to COVID-19 in comparison to periods before the pandemic. The extent of COVID-19’s effect on our operational and financial performance in the future will depend on future developments, including the duration, spread and intensity of the pandemic, our continued ability to manufacture and distribute our products, as well as any future government actions affecting consumers and the economy generally, all of which are uncertain and difficult to predict considering the rapidly evolving landscape.
For additional information on the impacts and our response to the coronavirus pandemic, refer to “Management’s Discussion and Analysis of Financial Condition and Results of Operations” included in Exhibit 99.1 of the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2020.
21

RESULTS OF OPERATIONS
CONSOLIDATED RESULTS

| Three Months Ended |  | Nine Months Ended
| 3/31/2021 |  | 3/31/2020 |  | % Change |  | 3/31/2021 |  | 3/31/2020 |  | % Change
Net sales | $ | 1,781 |  |  | $ | 1,783 |  |  | — | % |  | $ | 5,539 |  |  | $ | 4,738 |  |  | 17 | %

| Three Months Ended March 31, 2021
| Percentage change versus the year-ago period
| Reported (GAAP) Net Sales Growth / (Decrease) | Reported Volume |  | Acquisitions & Divestitures | Foreign Exchange Impact | Price/Mix/Other (1) | Organic Sales Growth / (Decrease) (Non-GAAP) (2) | Organic Volume (3)
Health and Wellness | (8) | % | (11) | % |  | — | % | — | % | 3 | % | (8) | % | (11) | %
Household | 6 |  | 4 |  |  | — |  | — |  | 2 |  | 6 |  | 4 |
Lifestyle | — |  | (1) |  |  | — |  | — |  | 1 |  | — |  | (1) |
International | 9 |  | 2 |  |  | 7 |  | (2) |  | 7 |  | 4 |  | (3) |
Total | — | % | (4) | % |  | 1 | % | — | % | 4 | % | (1) | % | (5) | %
| Nine Months Ended March 31, 2021
| Percentage change versus the year-ago period
| Reported (GAAP) Net Sales Growth / (Decrease) | Reported Volume |  | Acquisitions & Divestitures | Foreign Exchange Impact | Price/Mix/Other (1) | Organic Sales Growth / (Decrease) (Non-GAAP) (2) | Organic Volume (3)
Health and Wellness | 19 | % | 15 | % |  | — | % | — | % | 4 | % | 19 | % | 15 | %
Household | 20 |  | 14 |  |  | — |  | — |  | 6 |  | 20 |  | 14 |
Lifestyle | 8 |  | 8 |  |  | — |  | — |  | — |  | 8 |  | 8 |
International | 17 |  | 13 |  |  | 8 |  | (4) |  | 7 |  | 13 |  | 6 |
Total | 17 | % | 13 | % |  | 1 | % | — | % | 4 | % | 16 | % | 12 | %

(1) This represents the net impact on net sales growth / (decrease) from pricing actions, mix and other factors.
(2) Organic sales growth / (decrease) is defined as net sales growth / (decrease) excluding the effect of any acquisitions and divestitures as well as changes in foreign exchange rate.
(3) Organic volume represents volume excluding the effect of any acquisitions and divestitures. In the three months ended March 31, 2021, the volume impact of acquisitions was 5% and 1% for International and Total Company, respectively. In the nine months ended March 31, 2021, the volume impact of acquisitions was 7% and 1% for International and Total Company, respectively.
Net sales in the current three month period was essentially flat when compared to the prior period, reflecting lower sales in the Health and Wellness reportable segment, partially offset by sales growth in the Household and International reportable segments. Volume decreased by 4% versus the prior period. The variance between volume growth and net sales growth was primarily due to the impact of lower trade promotion spending and favorable mix.
Net sales in the current nine month period increased by 17%, reflecting higher shipments across all reportable segments driven by increased demand due to COVID-19 and related behavioral shifts. Volume increased by 13% versus the prior period. The variance between volume growth and net sales growth was primarily due to the impact of favorable mix, partially offset by unfavorable foreign currency exchange rates.
22

| Three Months Ended |  | Nine Months Ended
| 3/31/2021 |  | 3/31/2020 |  | % Change |  | 3/31/2021 |  | 3/31/2020 |  | % Change
Gross profit | $ | 774 |  |  | $ | 832 |  |  | (7) | % |  | $ | 2,531 |  |  | $ | 2,134 |  |  | 19 | %
Gross margin | 43.5 | % |  | 46.7 | % |  |  |  | 45.7 | % |  | 45.0 | % |  |

Gross margin, defined as gross profit as a percentage of net sales, decreased by 320 basis points in the current three month period from 46.7% to 43.5%. The decrease was primarily driven by higher manufacturing and logistics costs and unfavorable commodity costs, partially offset by lower trade promotion spending and the benefit of cost savings initiatives.
Gross margin increased by 70 basis points in the current nine month period from 45.0% to 45.7%. The increase was primarily driven by higher volume, cost savings, and lower trade promotion spending, partially offset by higher manufacturing and logistics costs.

| Three Months Ended
|  |  |  |  |  |  | % of Net Sales
| 3/31/2021 |  | 3/31/2020 |  | % Change |  | 3/31/2021 |  | 3/31/2020
Selling and administrative expenses | $ | 237 |  |  | $ | 269 |  |  | (12) | % |  | 13.3 | % |  | 15.1 | %
Advertising costs | 200 |  |  | 184 |  |  | 9 |  |  | 11.2 |  |  | 10.3 |
Research and development costs | 32 |  |  | 39 |  |  | (18) |  |  | 1.8 |  |  | 2.2 |
| Nine Months Ended
|  |  |  |  |  |  | % of Net Sales
| 3/31/2021 |  | 3/31/2020 |  | % Change |  | 3/31/2021 |  | 3/31/2020
Selling and administrative expenses | $ | 744 |  |  | $ | 690 |  |  | 8 | % |  | 13.4 | % |  | 14.6 | %
Advertising costs | 566 |  |  | 461 |  |  | 23 |  |  | 10.2 |  |  | 9.7
Research and development costs | 104 |  |  | 103 |  |  | 1 |  |  | 1.9 |  |  | 2.2

Selling and administrative expenses, as a percentage of net sales, decreased by 180 basis points and 120 basis points in the current three and nine month periods, respectively. The change in the current three month period was primarily due to lower incentive compensation expenses. The change in the current nine month period was primarily due to increased investments in several growth opportunities.
Advertising costs, as a percentage of net sales, increased by 90 basis points and 50 basis points in the current three and nine month periods, respectively. The increase in advertising expenses reflected the Company’s continued support behind its brands. The Company’s U.S. retail advertising spend as a percentage of net sales was approximately 12% in the current and prior three month periods.
Research and development costs, as a percentage of net sales, decreased by 40 basis points and 30 basis points in the current three and nine month periods, respectively. The decrease in research and development expenses was primarily due to lower incentive compensation expenses in the current three month period. The Company continues to invest behind product innovation and cost savings.
Goodwill, trademark and other asset impairments, Interest expense, Other (income) expense, net, and the effective tax rate on earnings

| Three Months Ended |  | Nine Months Ended
| 3/31/2021 |  | 3/31/2020 |  | 3/31/2021 |  | 3/31/2020
Goodwill, trademark and other asset impairments | $ | 329 |  |  | $ | — |  |  | $ | 329 |  |  | $ | — |
Interest expense | 25 |  |  | 24 |  |  | 74 |  |  | 74 |
Other (income) expense, net | 10 |  |  | 19 |  |  | (85) |  |  | 16 |
Effective tax rate on earnings (losses) | (1.4) | % |  | 18.9 | % |  | 22.5 | % |  | 20.4 | %

Goodwill, trademark and other asset impairments of $329 in the current three and nine month periods reflect non-cash impairment charges related to goodwill, trademarks, and other assets held by the VMS business (included within the Health and Wellness segment). See Notes to Condensed Consolidated Financial Statements for further information.
23

Other (income) expense, net was $10 and $19 in the current and prior three month periods, respectively, and ($85) and $16 in the current and prior nine month periods, respectively. The variance between the current and prior three month periods was not significant. The variance between the current and prior nine month periods was primarily due to the one-time, non-cash remeasurement gain recognized in the current period from the Company’s previously held equity interest in the Saudi joint venture in the first quarter of fiscal year 2021 (see Notes to Condensed Consolidated Financial Statements).
The effective tax rate on earnings (losses) was (1.4)% and 22.5% for the current three and nine month periods, respectively, and 18.9% and 20.4% for the prior three and nine month periods, respectively. The substantially lower tax rate on loss before income taxes in the current three month period and higher tax rate on earnings before income taxes in the current nine month period were driven by the partial non-deductibility of impaired VMS goodwill.
Diluted net earnings (losses) per share

| Three Months Ended |  | Nine Months Ended
| 3/31/2021 |  | 3/31/2020 |  | % Change |  | 3/31/2021 |  | 3/31/2020 |  | % Change
Diluted net earnings (losses) per share | $ | (0.49) |  |  | $ | 1.89 |  |  | (126) | % |  | $ | 4.78 |  |  | $ | 4.94 |  |  | (3) | %

Diluted net earnings (losses) per share (EPS) decreased by $2.38, or 126%, in the current three month period, primarily due to the non-cash impairment charges on assets held by the VMS business and lower gross margin, partially offset by lower selling and administrative expenses.
Diluted net earnings per share decreased by $0.16, or 3%, in the current nine month period, primarily due to the non-cash impairment charges on assets held by the VMS business, increased advertising investments and higher selling and administrative expenses, partially offset by gross margin expansion and the remeasurement gain recognized on the previously held equity interest in the Saudi joint venture.
SEGMENT RESULTS
The following presents the results of operations from the Company’s reportable segments and certain unallocated costs reflected in Corporate (see Notes to Condensed Consolidated Financial Statements for a reconciliation of segment results to consolidated results):
Health and Wellness

| Three Months Ended |  | Nine Months Ended
| 3/31/2021 |  | 3/31/2020 |  | % Change |  | 3/31/2021 |  | 3/31/2020 |  | % Change
Net sales | $ | 680 |  |  | $ | 736 |  |  | (8) | % |  | $ | 2,310 |  |  | $ | 1,944 |  |  | 19 | %
Earnings (losses) before income taxes | (183) |  |  | 210 |  |  | (187) |  |  | 315 |  |  | 514 |  |  | (39) |

Volume, net sales and earnings (losses) before income taxes decreased by 11%, 8% and 187%, respectively, during the current three month period. The volume and sales decreases were primarily driven by lower shipments in Cleaning and Professional Products as well as supply constraints for some key products. The variance between volume and net sales was primarily due to lower trade promotion spending. The decrease in earnings (losses) before income taxes in the current period was primarily due to the non-cash impairment charges on assets held by the VMS business, higher manufacturing and logistics costs, and net sales decline.
Volume, and net sales increased by 15%, and 19%, respectively, and earnings before income taxes decreased by 39%, during the current nine month period. The volume and sales growth reflected higher shipments in Cleaning and Professional Products portfolios due to greater demand inside and outside of the home. The variance between volume and net sales was primarily due to lower trader promotion and favorable mix. The decrease in earnings before income taxes in the current period was primarily due to the non-cash impairment charges on assets held by the VMS business, higher manufacturing and logistics costs, and higher advertising investment, partially offset by net sales growth.
24

Household

| Three Months Ended |  | Nine Months Ended
| 3/31/2021 |  | 3/31/2020 |  | % Change |  | 3/31/2021 |  | 3/31/2020 |  | % Change
Net sales | $ | 510 |  |  | $ | 480 |  |  | 6 | % |  | $ | 1,421 |  |  | $ | 1,183 |  |  | 20 | %
Earnings before income taxes | 97 |  |  | 114 |  |  | (15) |  |  | 266 |  |  | 190 |  |  | 40 |

Volume and net sales increased by 4% and 6%, respectively, and earnings before income taxes decreased by 15%, during the current three month period. The volume growth reflected higher shipments in Grilling from higher consumer demand. The variance between volume and net sales was primarily due to favorable mix and lower trade promotion spending. The decrease in earnings before income taxes was mainly due to higher manufacturing and logistics costs, unfavorable commodity costs, and higher advertising investments, partially offset by net sales growth.
Volume, net sales and earnings before income taxes increased by 14%, 20% and 40%, respectively, during the current nine month period. The volume growth reflected higher shipments across all SBUs, primarily driven by strong consumer demand. The variance between volume and net sales was primarily due to favorable mix and lower trade promotion spending. The increase in earnings before income taxes was mainly due to net sales growth, partially offset by higher manufacturing and logistics costs and higher advertising investments.
Lifestyle

| Three Months Ended |  | Nine Months Ended
| 3/31/2021 |  | 3/31/2020 |  | % Change |  | 3/31/2021 |  | 3/31/2020 |  | % Change
Net sales | $ | 293 |  |  | $ | 294 |  |  | — | % |  | $ | 928 |  |  | $ | 856 |  |  | 8 | %
Earnings before income taxes | 68 |  |  | 80 |  |  | (15) |  |  | 259 |  |  | 242 |  |  | 7 |

Volume and earnings before income taxes decreased by 1% and 15%, respectively, and net sales were essentially flat during the current three month period as compared to the prior period. The volume decrease was primarily driven by lower shipments of Natural Personal Care and Brita water filtration products, partially offset by higher shipments in Food products. The decrease in earnings before income taxes was primarily due to higher manufacturing and logistics costs.
Volume, net sales and earnings before income taxes increased by 8%, 8% and 7%, respectively, during the current nine month period. Both volume growth and net sales growth were primarily driven by higher shipments of Food and Brita water filtration products mainly due to greater demand by consumers and strategic brand investments. The Natural Personal Care business declined as the brand continued to adapt to new consumer shopping and usage habits. The increase in earnings before income taxes was primarily due to net sales growth, partially offset by higher manufacturing and logistics costs.
International

| Three Months Ended |  | Nine Months Ended
| 3/31/2021 |  | 3/31/2020 |  | % Change |  | 3/31/2021 |  | 3/31/2020 |  | % Change
Net sales | $ | 298 |  |  | $ | 273 |  |  | 9 | % |  | $ | 880 |  |  | $ | 755 |  |  | 17 | %
Earnings before income taxes | 30 |  |  | 36 |  |  | (17) |  |  | 184 |  |  | 106 |  |  | 74 |

Volume and net sales increased by 2% and 9%, respectively, and earnings before income taxes decreased by 17% during the current three month period. The volume increase was driven by higher shipments from ongoing demand for disinfecting and other household products in most geographic regions, as well as the impact of the Saudi joint venture acquisition. The variance between volume and net sales was mainly due to favorable mix and the benefit of price increases implemented to offset inflation in certain markets, partially offset by the impact of unfavorable foreign currency exchange rates. The decrease in earnings before income taxes was primarily due to higher manufacturing and logistics costs, unfavorable foreign currency exchange rates and higher commodity costs, partially offset by net sales growth.
Volume, net sales and earnings before income taxes increased by 13%, 17% and 74%, respectively, during the current nine month period. The volume increase was primarily driven by higher shipments from ongoing demand for disinfecting and other household products in every geographic region, as well as the impact of the Saudi joint venture acquisition. The variance between volume and net sales was mainly due to favorable mix and the benefit of price increases implemented to offset inflation, partially offset by the impact of unfavorable foreign currency exchange rates. The increase in earnings before income taxes was primarily due to the remeasurement gain recognized on the previously held equity interest in the Saudi joint venture.
25

Argentina
Effective July 1, 2018, under the requirements of U.S. GAAP, Argentina was designated as a highly inflationary economy, and as a result the U.S. dollar replaced the Argentine peso as the functional currency of the Company’s subsidiaries in Argentina. Consequently, gains and losses from non-U.S. dollar denominated monetary assets and liabilities of Clorox Argentina are recognized in Other (income) expense, net in the consolidated statement of earnings. The business environment in Argentina continues to be challenging due to significant volatility in Argentina’s currency, high inflation, an economic recession and impacts of COVID-19 that include temporary strict price controls. As of March 31, 2021 and June 30, 2020, the net asset position, excluding goodwill, of Clorox Argentina was $45 and $44, respectively. Of these net assets, cash balances were approximately $9 and $19 as of March 31, 2021 and June 30, 2020, respectively. Net sales from Clorox Argentina represented approximately 2% of the Company’s consolidated net sales for the nine months ended March 31, 2021 and the fiscal year ended June 30, 2020.
For additional information on the impacts of, and our response to, the business environment in Argentina, refer to “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” included in the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2020.
Corporate
Corporate includes certain non-allocated administrative costs, interest income, interest expense and various other non-operating income and expenses.

| Three Months Ended |  | Nine Months Ended
| 3/31/2021 |  | 3/31/2020 |  | % Change |  | 3/31/2021 |  | 3/31/2020 |  | % Change
Losses before income taxes | $ | (71) |  |  | $ | (143) |  |  | (50) | % |  | $ | (225) |  |  | $ | (262) |  |  | (14) | %

Losses before income taxes decreased by $72 in the current three month period primarily due to lower employee and incentive compensation and COVID-19 related expenses. Losses before income taxes decreased by $37 in the current nine month period primarily due to lower COVID-19 related expenses.
26

FINANCIAL POSITION AND LIQUIDITY
The Company’s financial condition and liquidity remained strong as of March 31, 2021. The following table summarizes cash activities:

| Nine Months Ended
| 3/31/2021 |  | 3/31/2020
Net cash provided by operations | $ | 893 |  |  | $ | 806 |
Net cash used for investing activities | (341) |  |  | (145) |
Net cash used for financing activities | (944) |  |  | (261) |

Operating Activities
Net cash provided by operations was $893 in the current nine month period, compared with $806 in the prior nine month period. The increase was primarily driven by the Company’s profitable sales growth, partially offset by higher tax payments and higher employee incentive compensation payments made in the current nine month period versus the prior period. Working capital changes were essentially flat in the comparative period (increased inventories in the current year primarily to meet customer demand, offset by cash inflows from collections from increased quarter-end sales in the prior fiscal year, and higher payables in the current period due to the extension of payment terms with suppliers and increased production levels primarily to improve inventory availability).
Investing Activities
Net cash used for investing activities was $341 in the current nine month period, compared with $145 in the prior nine month period. The year-over-year increase was mainly due to the acquisition of additional interest in the Company's Saudi joint venture and higher capital spending to increase manufacturing capacity in the current nine month period.
Financing Activities
Net cash used for financing activities was $944 in the current nine month period, compared with $261 in the prior nine month period. The year-over-year increase was mainly due to higher treasury stock repurchases in the current nine month period and net cash sourced from short-term borrowings in the prior period.
Capital Resources and Liquidity
Global financial markets have experienced a significant increase in volatility due to heightened uncertainty over the adverse economic impact caused by the COVID-19 outbreak. Notwithstanding these potential adverse market conditions, the Company believes it will have the funds necessary to support our short-term liquidity and operating needs based on our anticipated ability to generate positive cash flows from operations in the future, access to capital markets enabled by our strong short-term and long-term credit ratings, and current borrowing availability under the credit agreement.
Credit Arrangements
As of March 31, 2021, the Company maintained a $1,200 revolving credit agreement that matures in November 2024 (the Credit Agreement). There were no borrowings under the Credit Agreement as of March 31, 2021 and June 30, 2020, and the Company believes that borrowings under the Credit Agreement are and will continue to be available for general corporate purposes. The Credit Agreement includes certain restrictive covenants and limitations. The primary restrictive covenant is a minimum ratio of 4.0, calculated as total earnings before interest, taxes, depreciation and amortization and other similar non-cash charges (Consolidated EBITDA) to total interest expense for the trailing four quarters (Interest Coverage ratio), as defined and described in the Credit Agreement. Refer to the section entitled “Non-GAAP Financial Measures” below for further discussion of these measures.
27

The following table sets forth the calculation of the Interest Coverage ratio as of March 31, 2021, using Consolidated EBITDA for the trailing four quarters, as contractually defined in the Credit Agreement:

| Twelve Months Ended
| 3/31/2021
Net earnings | $ | 929 |
Add back: |
Interest expense | 99 |
Income tax expense | 265 |
Depreciation and amortization | 204 |
Non-cash asset impairment charges(1) | 330 |
Deduct: |
Interest income | (4) |
Non-recurring, non-cash gain(2) | (85) |
Consolidated EBITDA | $ | 1,738 |
Interest expense | $ | 99 |
Interest Coverage ratio | 17.6 |

(1) Includes goodwill, trademark and other asset impairments recorded impacting the VMS SBU (see Notes to Condensed Consolidated Financial Statements)
(2) Non-recurring, non-cash gain from the remeasurement of the Company’s previously held investment in its Saudi joint venture (see Notes to Condensed Consolidated Financial Statements).
The Company was in compliance with all restrictive covenants and limitations in the Credit Agreement as of March 31, 2021, and anticipates being in compliance with all restrictive covenants for the foreseeable future. The Company continues to monitor the financial markets and assess its ability to continue to draw on the Credit Agreement, and currently expects it will continue to have access to borrowings under the Credit Agreement.
As of March 31, 2021, the Company maintained $35 of foreign and other credit lines, of which $8 was outstanding.
Stock Repurchases and Dividend Payments
As of March 31, 2021, the Company had two stock repurchase programs: an open-market purchase program with an authorized aggregate purchase amount of up to $2,000, which has no expiration date, and a program to offset the anticipated impact of dilution related to stock-based awards (the Evergreen Program), which has no authorization limit on the dollar amount and no expiration date.
Stock repurchases under the two stock repurchase programs were as follows for the periods indicated:

| Three Months Ended |  | Nine Months Ended
| 3/31/2021 |  | 3/31/2020 |  | 3/31/2021 |  | 3/31/2020
| Amount |  | Shares (in thousands) |  | Amount |  | Shares (in thousands) |  | Amount |  | Shares (in thousands) |  | Amount |  | Shares (in thousands)
Open-market purchase program | $ | 200 |  |  | 1,088 |  |  | $ | — |  |  | — |  |  | $ | 200 |  |  | 1,088 |  |  | $ | 85 |  |  | 577 |
Evergreen Program | 105 |  |  | 560 |  |  | 30 |  |  | 184 |  |  | 405 |  |  | 1,984 |  |  | 134 |  |  | 847 |
Total stock repurchases | $ | 305 |  |  | 1,648 |  |  | $ | 30 |  |  | 184 |  |  | $ | 605 |  |  | 3,072 |  |  | $ | 219 |  |  | 1,424 |

Dividends per share declared and total dividends paid to Clorox stockholders were as follows for the periods indicated:

| Three Months Ended |  | Nine Months Ended
| 3/31/2021 |  | 3/31/2020 |  | 3/31/2021 |  | 3/31/2020
Dividends per share declared | $ | 1.11 |  |  | $ | 1.06 |  |  | $ | 3.33 |  |  | $ | 3.18 |  |
Total dividends paid | 140 |  |  | 133 |  |  | 420 |  |  | 399 |  |

28

CONTINGENCIES
See Notes to Condensed Consolidated Financial Statements for information on the Company’s contingencies.
RECENTLY ISSUED ACCOUNTING STANDARDS
See Notes to Condensed Consolidated Financial Statements for a summary of recently issued accounting standards relevant to the Company.
NON-GAAP FINANCIAL MEASURES
The non-GAAP financial measures that are included in this MD&A and the reasons management believes they are useful to investors are described below. These measures should be considered supplemental in nature and are not intended to be a substitute for the related financial information prepared in accordance with U.S. GAAP. In addition, these measures may not be the same as similarly named measures presented by other companies.
The Company uses the term Consolidated EBITDA because it is a term used in the Credit Agreement. As defined in the Credit Agreement, Consolidated EBITDA represents earnings before interest, taxes, depreciation and amortization, and other similar non-cash charges (such as non-cash asset impairment charges and other non-cash, non-recurring gains or losses). Interest Coverage ratio is the ratio of Consolidated EBITDA to interest expense. The Company’s management believes disclosure of Consolidated EBITDA provides useful information to investors because it is used in determining compliance with the primary restrictive covenant in the Credit Agreement. For additional discussion of the Interest Coverage ratio and a reconciliation of Consolidated EBITDA to net earnings, see “Financial Position and Liquidity - Financing Activities - Credit Arrangements” above.
Organic sales growth / (decrease) is defined as net sales growth / (decrease) excluding the effect of foreign exchange rate changes and any acquisitions and divestitures. Management believes that the presentation of organic sales growth / (decrease) is useful to investors because it excludes sales from any acquisitions and divestitures, which results in a comparison of sales only from the businesses that the Company was operating throughout the relevant periods, and the impact of foreign exchange rate changes, which are out of the control of the Company and management.
The following table provides a reconciliation of organic sales growth / (decrease) (non-GAAP) to net sales growth / (decrease) (GAAP), the most comparable GAAP measure:

| Three Months Ended March 31, 2021
| Percentage change versus the year-ago period
| Health and Wellness |  | Household |  | Lifestyle |  | International |  | Total
Net sales growth / (decrease) (GAAP) | (8) | % |  | 6 | % |  | — | % |  | 9 | % |  | — | %
Add: Foreign Exchange | — |  |  | — |  |  | — |  |  | 2 |  |  | — |
Add/(Subtract): Divestitures/Acquisitions | — |  |  | — |  |  | — |  |  | (7) |  |  | (1) |
Organic sales growth / (decrease) (non-GAAP) | (8) | % |  | 6 | % |  | — | % |  | 4 | % |  | (1) | %
| Nine Months Ended March 31, 2021
| Percentage change versus the year-ago period
| Health and Wellness |  | Household |  | Lifestyle |  | International |  | Total
Net sales growth / (decrease) (GAAP) | 19 | % |  | 20 | % |  | 8 | % |  | 17 | % |  | 17 | %
Add: Foreign Exchange | — |  |  | — |  |  | — |  |  | 4 |  |  | — |
Add/(Subtract): Divestitures/Acquisitions | — |  |  | — |  |  | — |  |  | (8) |  |  | (1) |
Organic sales growth / (decrease) (non-GAAP) | 19 | % |  | 20 | % |  | 8 | % |  | 13 | % |  | 16 | %

29

Cautionary Statement
This Report, including the exhibits hereto and the information incorporated by reference herein, contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including, among others, statements related to the expected or potential impact of the COVID-19 pandemic, and the related responses of governments, consumers, customers, suppliers, employees and the Company, on our business, operations, employees, financial condition and results of operations, and any such forward-looking statements, whether concerning the COVID-19 pandemic or otherwise, involve risks, assumptions and uncertainties. Except for historical information, statements about future volumes, sales, organic sales growth, foreign currencies, costs, cost savings, margins, earnings, earnings attributable to the Company, earnings per share, diluted earnings per share, foreign currency exchange rates, tax rates, cash flows, plans, objectives, expectations, growth or profitability are forward-looking statements based on management’s estimates, beliefs, assumptions and projections. Words such as “could,” “may,” “expects,” “anticipates,” “targets,” “goals,” “projects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “will,” “predicts,” and variations on such words, and similar expressions that reflect our current views with respect to future events and operational, economic and financial performance are intended to identify such forward-looking statements. These forward-looking statements are only predictions, subject to risks and uncertainties, and actual results could differ materially from those discussed. Important factors that could affect performance and cause results to differ materially from management’s expectations, or could affect the Company’s ability to achieve its strategic goals, are described in the sections entitled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2020 and in this Report, as updated from time to time in the Company’s Securities and Exchange Commission filings. These factors include, but are not limited to, the uncertainties relating to the continued impact of COVID-19 on the Company’s business, operations, employees, financial condition and results of operations, as well as:
•intense competition in the Company’s markets;
•the impact of the changing retail environment, including the growth of alternative retail channels and business models, and changing consumer preferences;
•the impact of COVID-19 on the availability of, and efficiency of the supply, manufacturing and distribution systems for, the Company’s products, including any significant disruption to such systems;
•long-term changes in consumer preference or demand for the Company’s products as a result of any shortages or lack of availability of any products in the near-term;
•risks related to supply chain issues and product shortages as a result of reliance on a limited base of suppliers and the significant increase in demand for disinfecting and other products due to the COVID-19 pandemic;
•dependence on key customers and risks related to customer consolidation and ordering patterns;
•risks related to the Company’s use of and reliance on information technology systems, including potential security breaches, cyber-attacks, privacy breaches or data breaches that result in the unauthorized disclosure of consumer, customer, employee or Company information, or service interruptions, especially at a time when a large number of the Company’s employees are working remotely and accessing its technology infrastructure remotely;
•risks relating to acquisitions, including the recent acquisition of the majority interest in the company’s Saudi joint venture, new ventures and divestitures, and associated costs, including for asset impairment charges related to, among others, intangible assets, including trademarks, and goodwill, in particular the impairment charges relating to the carrying value of the company’s Vitamins, Minerals and Supplements business;
•unfavorable worldwide, regional and local economic and financial market conditions, including as a result of fear of exposure to or actual impacts of a widespread disease outbreak, such as COVID-19;
•the Company’s ability to maintain its business reputation and the reputation of its brands and products;
•lower revenue, increased costs or reputational harm resulting from government actions and regulations;
•the ability of the Company to successfully manage global political, legal, tax and regulatory risks, including changes in regulatory or administrative activity;
•the ability of the Company to drive sales growth, increase prices and market share, grow its product categories and manage favorable product and geographic mix;
•volatility and increases in commodity costs such as resin, sodium hypochlorite and agricultural commodities, and increases in energy, transportation or other costs;
30

•risks related to international operations and international trade, including foreign currency fluctuations, such as devaluations, and foreign currency exchange rate controls, including periodic changes in such controls; changes in U.S. immigration or trade policies, including the imposition of new or additional tariffs; labor claims and labor unrest; inflationary pressures, particularly in Argentina; impact of the United Kingdom’s exit from, and the related on-going negotiations with, the European Union; government-imposed price controls or other regulations; potential negative impact and liabilities from the use, storage and transportation of chlorine in certain international markets where chlorine is used in the production of bleach; widespread health emergencies, such as COVID-19; and the possibility of nationalization, expropriation of assets or other government action;
•the facilities of the Company and its suppliers being subject to disruption by events beyond the Company’s control, including work stoppages, cyber-attacks, natural disasters, disease outbreaks or pandemics, such as COVID-19, and terrorism;
•the ability of the Company to innovate and to develop and introduce commercially successful products, or expand into adjacent categories and countries;
•the impact of product liability claims, labor claims and other legal, governmental or tax proceedings, including in foreign jurisdictions and in connection with any product recalls;
•the ability of the Company to implement and generate cost savings and efficiencies;
•the success of the Company’s business strategies;
•risks related to additional increases in the estimated fair value of The Procter & Gamble Company’s interest in the Glad business;
•the accuracy of the Company’s estimates and assumptions on which its financial projections, including any sales or earnings guidance or outlook it may provide from time to time, are based;
•the Company’s ability to attract and retain key personnel;
•environmental matters, including costs associated with the remediation and monitoring of past contamination, and possible increases in costs resulting from actions by relevant regulators, and the handling and/or transportation of hazardous substances;
•increased focus by governmental and non-governmental organizations, customers, consumers and investors on sustainability issues, including those related to climate change;
•the Company’s ability to effectively utilize, assert and defend its intellectual property rights;
•any infringement or claimed infringement by the Company of third-party intellectual property rights;
•the effect of the Company’s indebtedness and credit rating on its business operations and financial results;
•the Company’s ability to access capital markets and other funding sources, as well as continued or increased market volatility;
•the Company’s ability to pay and declare dividends or repurchase its stock in the future;
•uncertainties relating to tax positions, tax disputes and any changes in tax rates and regulations on the Company;
•the Company’s ability to maintain an effective system of internal controls;
•the impacts of potential stockholder activism; and
•risks related to the Company’s discontinuation of operations in Venezuela.
The Company’s forward-looking statements in this Report are based on management’s current views, beliefs, assumptions and expectations regarding future events and speak only as of the date of this Report. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by the federal securities laws.
In this Report, unless the context requires otherwise, the terms “the Company,” “Clorox,” “we,” “us,” and “our” refer to The Clorox Company and its subsidiaries.
31

Item 3. Quantitative and Qualitative Disclosures About Market Risk
There have not been any material changes to the Company’s market risk since June 30, 2020. For additional information, refer to “Management’s Discussion and Analysis of Financial Condition and Results of Operations” included in Exhibit 99.1 of the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2020.
Item 4. Controls and Procedures
The Company’s management, with the participation of the Company’s Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of the Company’s disclosure controls and procedures as of the end of the period covered by this Report. Based on that evaluation, the Chief Executive Officer and Chief Financial Officer concluded that the Company’s disclosure controls and procedures, as of the end of the period covered by this Report, were effective such that the information required to be disclosed by the Company in reports filed under the Exchange Act is (i) recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and (ii) accumulated and communicated to management, including the Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.
No change in the Company’s internal control over financial reporting occurred during the third fiscal quarter of the fiscal year ending June 30, 2021, that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting.
32

PART II – OTHER INFORMATION
Item 1.A. Risk Factors
For information regarding Risk Factors, please refer to Item 1.A. in the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2020 and the information in “Cautionary Statement” included in this Report.
33

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
In May 2018, the Board of Directors authorized the Company to repurchase up to $2,000 million in shares of common stock on the open market (the 2018 Open-Market Program), which has no expiration date.
In August 1999, the Board of Directors authorized a stock repurchase program to reduce or eliminate dilution upon the issuance of common stock pursuant to the Company’s stock compensation plans (the Evergreen Program). In November 2005, the Board of Directors authorized the extension of the Evergreen Program to reduce or eliminate dilution in connection with issuances of common stock pursuant to the Company’s 2005 Stock Incentive Plan. The Evergreen Program has no expiration date and has no specified limit as to dollar amount and therefore is not included in column [d] below.
The following table sets forth the purchases of the Company’s securities by the Company and any affiliated purchasers within the meaning of Rule 10b-18(a)(3) (17 CFR 240.10b-18(a)(3)) during the third quarter of fiscal year 2021.

| [a] |  | [b] |  | [c] |  | [d]
Period | Total Number of Shares Purchased (1) |  | Average Price Paid per Share (2) |  | Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs |  | Maximum Number (or Approximate Dollar Value) of Shares that May Yet Be Purchased Under the Plans or Programs
January 1 to 31, 2021 | — |  |  | $ | — |  |  | — |  |  | $1,493 million
February 1 to 28, 2021 | 910,000 |  |  | 186.23 |  |  | 910,000 |  |  | $1,428 million
March 1 to 31, 2021 | 738,130 |  |  | 183.40 |  |  | 738,130 |  |  | $1,293 million
Total | 1,648,130 |  |  | $ | 184.96 |  |  | 1,648,130 |  |  |

____________________
(1)Of the shares purchased in February 2021, 560,000 shares were acquired pursuant to the Evergreen Program and 350,000 shares were acquired pursuant to the Open-Market Program. All shares purchased in March 2021 were acquired pursuant to the Open-Market Program.
(2)Average price paid per share in the period includes commission.
34

Item 6. Exhibits
See Exhibit Index below, which is incorporated by reference herein.
EXHIBIT INDEX
Exhibit No.

10.1 |  | The Clorox Company Annual Incentive Plan, amended and restated as of February 9, 2021.
10.2 |  | The Clorox Company Executive Incentive Compensation Plan, amended and restated as of February 9, 2021.
10.3 |  | The Clorox Company 2005 Stock Incentive Plan, First Amendment and Restatement as of November 14, 2012; Second Amendment and Restatement as of September 22, 2020; Third Amendment and Restatement as of February 9, 2021.
10.4 |  | Form of Nonqualified Stock Option Award Agreement under the Company’s 2005 Stock Incentive Plan.
10.5 |  | Form of Performance Share Award Agreement under the Company’s 2005 Stock Incentive Plan for awards made in 2021.
10.6 |  | Form of Restricted Stock Unit Award Agreement under the Company's 2005 Stock Incentive Plan (Annual Grant).
10.7 |  | Form of Restricted Stock Unit Award Agreement under the Company's 2005 Stock Incentive Plan (Off-Cycle Grant).
10.8 |  | Severance Plan for Clorox Executive Committee Members, third amended and restated effective February 9, 2021.
31.1 |  | Certification by the Chief Executive Officer of the Company Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2 |  | Certification by the Chief Financial Officer of the Company Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32 |  | Certification by the Chief Executive Officer and Chief Financial Officer of the Company Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.SCH |  | XBRL Taxonomy Extension Schema Document.
101.CAL |  | XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF |  | XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB |  | XBRL Taxonomy Extension Label Linkbase Document.
101.PRE |  | XBRL Taxonomy Extension Presentation Linkbase Document.
104 |  | Cover Page Interactive Data File (embedded within the Inline XBRL document and included in Exhibit 101).

35

SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

|  | THE CLOROX COMPANY
|  | (Registrant)
DATE: April 30, 2021 | BY | /s/ Jeffrey R. Baker
|  | Jeffrey R. Baker Vice President – Chief Accounting Officer and Corporate Controller

36